ERBA Diagnostics (ERB) 10-K 14 Apr 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Apr. 04, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'ERBA Diagnostics, Inc.	'	'
Entity Central Index Key	'0001095858	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'ERB	'	'
Entity Common Stock, Shares Outstanding	'	43,783,221	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$6,543,788

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash and cash equivalents	$4,031,071	$4,125,818
Accounts receivable, net	5,546,715	5,643,359
Inventories, net	6,494,173	5,838,150
Related party receivables	1,834,732	725,806
Other current assets	395,196	219,636
Total current assets	18,301,887	16,552,769
PROPERTY, PLANT AND EQUIPMENT:	'	'
Land	352,957	352,957
Buildings and improvements	3,136,434	3,068,607
Machinery and equipment	3,831,213	3,731,139
Furniture and fixtures	2,216,720	2,050,241
Property,plant and equipment,Gross	9,537,324	9,202,944
Less: accumulated depreciation	-7,976,121	-7,605,984
Property, plant and equipment, net	1,561,203	1,596,960
OTHER LONG-TERM ASSETS:	'	'
Intangible assets, net	1,480,151	1,812,048
Goodwill	3,494,619	3,494,619
Equipment on lease, net	586,785	585,321
Product license	226,349	282,936
Restricted deposits	204,686	148,040
Other assets	18,786	81,075
Total other long-term assets	6,011,376	6,404,039
Total assets	25,874,466	24,553,768
CURRENT LIABILITIES:	'	'
Accounts payable	1,953,906	3,064,516
Capital lease obligation, current	0	21,947
Revolving line of credit	1,904,879	822,635
Other accrued expenses	2,894,430	2,809,447
Total current liabilities	6,753,215	6,718,545
OTHER LONG-TERM LIABILITIES:	'	'
Deferred tax liabilities	576,160	509,365
Other long-term liabilities	1,027,425	993,980
Total other long-term liabilities	1,603,585	1,503,345
Total liabilities	8,356,800	8,221,890
COMMITMENTS AND CONTINGENCIES	'	'
SHAREHOLDERS' EQUITY:	'	'
Common stock, par value $0.01, authorized 100,000,000 shares, issued and outstanding 43,658,221 in 2013 and 2012	436,582	436,582
Additional paid-in capital	53,081,370	52,947,370
Accumulated deficit	-35,861,343	-36,537,171
Accumulated other comprehensive loss	-138,943	-514,903
Total shareholders' equity	17,517,666	16,331,878
Total liabilities and shareholders' equity	$25,874,466	$24,553,768

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	43,658,221	43,658,221
Common stock, shares outstanding	43,658,221	43,658,221

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
NET REVENUE	$28,255,317	$19,349,004
COST OF SALES	14,442,815	10,257,367
Gross profit	13,812,502	9,091,637
OPERATING EXPENSES:	'	'
Selling	5,308,528	4,616,684
General and administrative	5,547,078	4,555,577
Research and development	1,920,171	1,122,537
Total operating expenses	12,775,777	10,294,798
Income (loss) from operations	1,036,725	-1,203,161
OTHER INCOME (EXPENSE), NET:	'	'
Interest income (expense)	-121,963	-39,808
Unrealized gain (loss) on foreign currency transactions	187,252	-55,793
Acquisition expenses	-211,045	-211,099
Other income (expense), net	-96,087	78,550
Total other income (expense), net	-241,843	-228,150
Income (loss) before provision for income taxes	794,882	-1,431,311
PROVISION FOR INCOME TAXES	119,054	122,045
Net income (loss)	675,828	-1,553,356
OTHER COMPREHENSIVE INCOME (LOSS):	'	'
Foreign currency translation adjustment	375,960	152,962
Total comprehensive income (loss)	$1,051,788	($1,400,394)
NET INCOME (LOSS) PER SHARE - Basic	$0.02	($0.04)
NET INCOME (LOSS) PER SHARE - Diluted	$0.01	($0.04)
WEIGHTED AVERAGE SHARES OUTSTANDING:	'	'
Basic (in shares)	43,658,221	36,947,292
Diluted (in shares)	48,542,706	36,947,292

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]
Balances at Dec. 31, 2011	$10,727,272	$343,915	$46,035,037	($34,983,815)	($667,865)
Balances (in shares) at Dec. 31, 2011	'	34,391,554	'	'	'
Issuance of common stock	6,950,000	92,667	6,857,333	0	0
Issuance of common stock (in shares)	'	9,266,667	'	'	'
Stock compensation expense	55,000	0	55,000	0	0
Foreign currency translation adjustment	152,962	0	0	0	152,962
Net income (loss)	-1,553,356	0	0	-1,553,356	0
Balances at Dec. 31, 2012	16,331,878	436,582	52,947,370	-36,537,171	-514,903
Balances (in shares) at Dec. 31, 2012	'	43,658,221	'	'	'
Stock compensation expense	134,000	0	134,000	0	0
Foreign currency translation adjustment	375,960	0	0	0	375,960
Net income (loss)	675,828	0	0	675,828	0
Balances at Dec. 31, 2013	$17,517,666	$436,582	$53,081,370	($35,861,343)	($138,943)
Balances (in shares) at Dec. 31, 2013	'	43,658,221	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income (loss)	$675,828	($1,553,356)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities-	'	'
Depreciation and amortization	960,070	726,214
Provision for doubtful accounts receivable	39,221	195,940
Provision for inventory obsolescence	17,652	377,486
Non-cash compensation	134,000	55,000
Deferred income tax provision	68,788	80,689
Changes in operating assets and liabilities, net of acquisition:	'	'
Accounts receivable	294,920	1,039,949
Inventories	-584,383	-179,128
Other current assets	-235,722	-60,585
Accounts payable and accrued expenses	-1,190,856	-116,953
Related party receivables	-1,125,161	-322,370
Other long-term liabilities	13,918	-41,180
Net cash provided by (used in) operating activities	-931,725	201,706
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Capital expenditures	-297,909	-105,233
Acquisition of equipment on lease, net	-217,167	-76,616
Acquisition of Drew Scientific, Inc., net of cash acquired	0	-6,453,404
Decrease in restricted deposits	0	12,797
Net cash (used in) investing activities	-515,076	-6,622,456
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds of share offering	0	6,950,000
Net proceeds from revolving line of credit	1,130,707	86,069
Capital lease payments	-21,947	-78,929
Net cash provided by financing activities	1,108,760	6,957,140
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	243,294	-63,816
NET INCREASE IN CASH AND CASH EQUIVALENTS	-94,747	472,574
CASH AND CASH EQUIVALENTS, beginning of year	4,125,818	3,653,244
CASH AND CASH EQUIVALENTS, end of year	4,031,071	4,125,818
SUPPLEMENTAL DISCLOSURES:	'	'
Income taxes paid	0	8,836
Interest paid	$28,156	$39,911

ORGANIZATION_AND_OPERATIONS

ORGANIZATION AND OPERATIONS	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	1  ORGANIZATION AND OPERATIONS
	As approved by the Company’s stockholders at the Company’s Annual Meeting of Stockholders held on June 15, 2012, and as previously approved by the Company’s Board of Directors, the Company’s name was changed from IVAX Diagnostics, Inc. to ERBA Diagnostics, Inc. (“ERBA Diagnostics” or the “Company”). The Company is a Delaware corporation and, through its subsidiaries, is engaged in developing, manufacturing and marketing diagnostic test kits, reagents and instruments for use in hospitals, reference laboratories, clinical laboratories, research laboratories, doctors’ offices and other commercial companies. The Company’s products and instrumentation are sold globally.
	On September 1, 2010, ERBA Diagnostics Mannheim GmbH, an in vitro diagnostics company headquartered in Germany (“ERBA Mannheim”), the parent company of which is Transasia Bio-Medicals Ltd. (“Transasia”), purchased all of the approximately 72.4% of the outstanding shares of the Company’s common stock then owned by the Debregeas-Kennedy Group for an aggregate purchase price of approximately $15,000,000, or $0.75 per share. As a result of this share acquisition, the consummation of the various transactions contemplated by the investment made by ERBA Mannheim pursuant to that certain Stock Purchase Agreement, as further described in Note 13, Related Party Transactions, including ERBA Mannheim’s purchase from the Company, and the Company’s issuance to ERBA Mannheim, of an aggregate of 15,333,334 shares of the Company’s common stock, and ERBA Mannheim’s exercise, in part, of the Warrant, as further described in Note 13, Related Party Transactions, for 600,000 shares of the Company’s common stock, ERBA Mannheim now beneficially owns, directly or indirectly, approximately 82.4% of the outstanding shares of the Company’s common stock.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The accompanying consolidated financial statements are presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include the accounts of ERBA Diagnostics, Inc. and its wholly-owned subsidiaries Diamedix Corporation (“Diamedix”), ImmunoVision, Inc. (“ImmunoVision”) and Delta Biologicals, S.r.l. (“Delta Biologicals”) and, from and after the acquisition date of October 3, 2012, Drew Scientific, Inc. and its subsidiaries (“Drew Scientific”) (as more fully described in Note 3, Acquisition of Drew Scientific, Inc.). All significant intra-entity balances and transactions have been eliminated in consolidation.
	Reclassifications
	Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current year’s presentation.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, at the date of and for the period of the consolidated financial statements. The Company’s actual results in subsequent periods may differ from the estimates and judgments used in the preparation of the accompanying consolidated financial statements. Significant estimates include the allowance for doubtful accounts, inventories, intangible assets, income and other tax accruals, stock based compensation, the computation of fair-value measurements related to the acquisition of Drew Scientific, the realization of long-lived assets and contingencies and litigation.
	Cash and Cash Equivalents
	The Company considers certain short-term investments in money market accounts with original maturities of three months or less to be cash equivalents.
	Accounts Receivable and Allowance for Doubtful Accounts
	The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained, particularly in Italy where payment cycles are longer than in the United States and in some instances may take in excess of a year to collect, for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been followed in accordance with the Company’s policies. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.
	The Company periodically receives payments based upon negotiated agreements with governmental regions in Italy, acting on behalf of hospitals located in the region, in satisfaction of previously outstanding accounts receivable balances. The Company may have anticipated collection of these amounts through a payment as described above and, therefore, not provided an allowance for doubtful accounts for these amounts. Future payments by governmental regions in Italy are possible and, as a result, the Company may consider the potential receipt of those payments in determining its allowance for doubtful accounts. If contemplated payments are not received when expected or at all, or if negotiated agreements are not complied with in a timely manner or cancelled, then the Company may provide additional allowances for doubtful accounts.
	The allowance for doubtful accounts was $1,064,739 and $995,662 as of December 31, 2013 and 2012, respectively, and activity for the years then ended was as follows:
			2013		2012
	Balance as of January 1		$	995,662	$	716,599
	Provision			39,559		625,935
	Write-offs			—		(361,229	)
	Effects of changes in foreign exchange rates			29,518		14,357
	Balance as of December 31		$	1,064,739	$	995,662
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market. Components of inventory cost include materials, labor and manufacturing overhead. In evaluating whether inventory is stated at the lower of cost or market, management considers such factors as the amount of inventory on hand, estimated time required to sell such inventory, remaining shelf life and current market conditions. Inventory costs associated with marketed products are capitalized, as are certain unapproved products prior to regulatory approval and product launch, based on management’s judgment of probable future economic benefit which includes an assessment of probability of future commercial use and net realizable value. With respect to instrumentation products, the Company purchases instrument parts and, in some cases, manufactures instrument components in preparation for the commercial launch of the instrument in amounts sufficient to support forecasted initial market demand. Inventory is not capitalized unless the product or instrument is considered to have a high probability of receiving regulatory approval. The Company may make this determination prior to its submission to the United States Food and Drug Administration (“FDA”) of a 510(k) application or other required regulatory submission. In determining probability, if the Company is aware of any specific risks or contingencies that are likely to adversely impact the expected regulatory approval process, then it would not capitalize the related inventory but would instead expense it as incurred. Additionally, the Company’s estimates of future instrumentation and diagnostic kit product demand, or judgment of probable future economic benefit, may prove to be inaccurate, in which case any resulting adjustments to the value of inventory would be recognized at the time of such determination. Reserves are provided as appropriate to reduce excess or obsolete inventories to the lower of cost or market. Inventories, net consist of the following as of December 31, 2013 and 2012:
			2013		2012
	Raw materials		$	3,123,380	$	1,712,199
	Work-in-process			624,454		664,880
	Finished goods			2,746,339		3,461,071
	Total inventories, net		$	6,494,173	$	5,838,150
	The Company regularly reviews inventory quantities on hand, which include components for current or future versions of products and instrumentation. If necessary, the Company records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements, as well as based upon the status of a product within the regulatory approval process. In accordance with the Company’s inventory accounting policy, the Company’s inventory balance at times includes components for current or future versions of products and instrumentation. Inventory reserves were approximately $1,129,000 and $816,000 as of December 31, 2013 and December 31, 2012, respectively.
	Our inventory balance as of December 31, 2012 included approximately $100,000 of inventory relating to our hepatitis product, substantially all of which has a shelf life exceeding five years, for which we obtained “CE Marking” approval in the European Union during 2011 and for which we have begun selling in certain markets. As a result of sales in 2013, the inventory balance has been depleted as of December 31, 2013.
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful lives of the assets as follows:
			Years
	Buildings and improvements			5 – 20
	Machinery and equipment			3 – 10
	Furniture and fixtures			3 – 10
	Costs of major additions and improvements are capitalized and expenditures for maintenance and repairs which do not extend the life of the assets are expensed. Upon sale or disposition of property, plant and equipment, the cost and related accumulated depreciation is eliminated from the accounts and any resulting gain or loss is credited or charged to operations.
	Depreciation expense was $393,462 and $326,917 during the years ended December 31, 2013 and 2012, respectively.
	Equipment on Lease, Net
	The cost of the Company’s owned instruments, which are placed under reagent rental programs at customer facilities for testing and usage of the Company’s products (see Note 2, Summary of Significant Accounting Policies, below under the heading Revenue Recognition), less accumulated amortization, consists of the following as of December 31, 2013 and 2012:
			2013		2012
	Equipment on lease, at cost		$	6,773,917	$	6,666,122
	Less accumulated amortization			6,187,132		6,080,801
			$	586,785	$	585,321
	Equipment on lease is typically amortized over three or five years. Amortization expense was $214,237 and $172,175 for the years ended December 31, 2013 and 2012, respectively.
	Intangible Assets
	Intangible assets relate to the acquisition of Drew Scientific (as more fully described in Note 3, Acquisition of Drew Scientific, Inc.) and consist of the following as of December 31, 2013 and 2012:
			Estimated Useful Life (Years)		As of December 31, 2013							As of December 31, 2012
					Gross			Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
					Amount					Amount		Amount				Amount
	Customer relationships			4.8	$	1,026,532		$	266,957	$	759,575	$	1,026,532	$	53,096	$	973,436
	Trademarks/ tradenames			10		512,701			64,087		448,614		512,701		12,817		499,884
	Patents			7		309,057			53,168		255,889		309,057		9,972		299,085
	Lease rights			2		47,140			31,067		16,073		47,140		7,497		39,643
					$	1,895,430		$	415,279	$	1,480,151	$	1,895,430	$	83,382	$	1,812,048
	Amortization expense is computed principally on a straight-line basis and for the next five years approximates:
	Years Ending December 31,
	2014		$	324,000
	2015			306,000
	2016			306,000
	2017			216,000
	2018			94,000
			$	1,228,000
	Amortization expense related to the acquired intangible assets for the years ended December 31, 2013 and 2012 amounted to $331,897 and $83,382, respectively.
	Long Lived Assets, Including Goodwill
Goodwill is attributed to the acquisitions of ImmunoVision and Drew Scientific and represents the excess of the cost over the fair value of nets assets acquired. The Company tests goodwill for possible impairment on an annual basis and at any other time events occur or circumstances indicate that the carrying amount of goodwill may be impaired. The first step required in the impairment analysis consists of a comparison of the fair value of the reporting unit with its carrying amount, including the goodwill.
For the annual test of its remaining goodwill at ImmunoVision, the Company determined fair value primarily based upon the income approach, which estimates the fair value based on the future discounted cash flows, rather than the market approach, which estimates the fair value based on market prices of comparable companies. The Company believes the income approach is more appropriate to determine the fair value at ImmunoVision and should therefore be more heavily weighted due to the fact that similar public companies comparable to ImmunoVision are difficult to identify and current market conditions are in a period of volatility with wide ranging multiples. Based upon this methodology, and utilizing significant assumptions in the income approach that included a forecasted cash flow period of five years, long-term annual growth rates of 3% for both years and a discount rate of 19% and 20% for 2013 and 2102, respectively, no impairment was recorded for the years ended December 31, 2013 or 2012.
The goodwill of Drew Scientific was also subjected to the annual testing for impairment and its value was determined by the Company with similar significant reliance on the income approach. This approach utilized significant assumptions including a forecasted cash flow period of five years, a long-term annual growth rate 3% and a discount rate of 19%. The market approach was not considered to be as reliable as the income approach due to the difficulty of identifying similar publicly traded companies comparable to Drew Scientific and the stock price volatility in the industry. The Company determined that the income approach is more appropriate, and, based upon the results of the Company’s analysis, no impairment was recorded during the year ended December 31, 2013.
The Company reviews its long-lived assets for impairment, including intangible assets and fixed assets that are held and used in its operations, whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such an event or change in circumstances occurs, then the Company will estimate the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the undiscounted future cash flows is less than the carrying amount of the related assets, then the Company will recognize an impairment loss. Assets to be disposed of are reclassified as assets held for sale at the lower of their carrying amount or fair value less costs to sell. Write-downs to fair value less disposal costs are reported as a part of loss from operations.
The Company does not believe that there were any events or changes in circumstances which indicate that the carrying amounts of its long-lived assets may not be recoverable as of December 31, 2013 and 2012, respectively.
Restricted Deposits
Long-term restricted deposits of $204,686 and $148,040 as of December 31, 2013 and 2012, respectively, consist primarily of cash deposits required as part of the sales tender process with governmental customers in Italy and cash deposits made in connection with capital and operating leases.
Foreign Currency Translation
The Company has operations that are located in Italy and is working to increase its presence in other international markets. Assets and liabilities as stated in the local reporting and functional currency are translated at the rate of exchange prevailing at the balance sheet date. Amounts in the consolidated statements of operations and comprehensive loss are translated at the average exchange rates for the period. The gains or losses that result from this process are shown in the “Accumulated Other Comprehensive Loss” in the consolidated statements of operations and comprehensive loss and consolidated statements of shareholders’ equity.
The Company does not use financial derivatives to hedge exchange rate fluctuations.
Financial Instruments
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and capital lease obligations approximate fair value due to the short-term maturity of the instruments. The Company does not speculate in the foreign exchange market.
Revenue Recognition
Revenue and the related cost of sales on sales of test kits and instruments are recognized when risk of loss and title passes, which is generally at the time of shipment. Net revenue is comprised of gross revenue less provisions for expected product returns, allowances, discounts and warranty claims. Provisions and discounts for the years ended December 31, 2013 and 2012 were not significant.
The Company recognizes milestone payments when earned, as evidenced by written acknowledgement from the collaborator, provided that the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, the milestone represents the culmination of an earnings process, the milestone payment is non-refundable and the Company’s past research and development services, as well as the Company’s ongoing commitment to provide research and development services under the collaboration, are charged at fees that are comparable to the fees that the Company customarily charges for similar research and development services.
The Company also owns instruments that it places, under “reagent rental” programs common to the industry, for periods of time at customer facilities for usage with the Company’s products (“Equipment on Lease”). The instrument system, which remains the property of the Company, is utilized by customers to expedite the performance of certain tests and its use, including any required instrument service, is paid for by the customer through reagent kit purchases over the agreed upon contract period, typically three to five years. Upon completion of the contract period, the instrument is returned to the Company.
Shipping and handling fees billed to customers are recognized in net revenue. Shipping and handling costs are included in cost of sales.
The taxes that the Company has collected from its customers and remitted to governmental authorities are presented in the Company’s consolidated statements of operations and comprehensive loss on a net basis. Many of the Company’s customers are tax exempt organizations.
Research and Development Costs
Research and development costs related to future products are expensed as incurred. As described in Note 13, Related Party Transactions, the Company entered into a contract research and development agreement with ERBA Mannheim during 2011. Expenses incurred pursuant to that contract are included in cost of sales as the related revenues are recorded from the achievement of milestones.
Foreign Currency Transactions
The Company has assets and liabilities held in foreign currency which are translated at period-end exchange rates, and revenues and expenses are translated at average rates prevailing during the period. Certain accounts receivable from customers are collected and certain accounts payable to vendors are payable in currencies other than the functional currencies of the Company. These amounts are adjusted to reflect period-end exchange rates. The Company recognized an unrealized gain on foreign currency transactions of $187,252 during the year ended December 31, 2013. The Company recognized an unrealized loss on foreign currency transactions of $55,793 during the year ended December 31, 2012.
Stock-Based Compensation Plans
Stock-based compensation expense for all share-based payment awards granted after January 1, 2006 is based on the grant-date fair value estimates. Compensation costs are recognized on a straight line basis over the requisite service period of the award, which is generally the option vesting term or immediately for options vested at the date of grant. Valuations are based on highly subjective assumptions about the future, including stock price volatility and exercise patterns. The fair value of share-based payment awards was estimated using the Black-Scholes option pricing model. Expected volatilities are based on the historical volatility of the Company’s stock. The Company uses historical data to estimate option exercise and employee terminations. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the United States Treasury yield curve in effect at the time of the grant. The Company estimates forfeitures for employee stock options and recognizes the compensation costs for only those options expected to vest. Forfeiture rates are determined for two groups, for directors and senior management and for all other employees, based upon historical experience. Estimated forfeitures are adjusted to actual forfeiture experience as needed. The cumulative effect of the change in forfeiture rates was immaterial for the years ended December 31, 2013 and 2012.
As of December 31, 2013, the Company had stock-based employee compensation plans as described in Note 10, Shareholders’ Equity. The Company recorded total compensation expense of $134,000 for the year ended December 31, 2013 and $55,000 for the year ended December 31, 2012.
Income (Loss) per Share
Basic income (loss) per share excludes any dilution. It is based upon the weighted average number of shares of common stock outstanding during the period. Diluted loss per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock. As of December 31, 2013 and 2012, 450,000 and 15,854,204 shares of common stock, respectively, underlying stock options and warrants were not included in computing diluted income per share because their effects would be anti-dilutive.
Fair Value Measurement
The Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification Topic 820 (“ASC 820”) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability, in an orderly transaction between market participants at the measurement date.
FASB ASC framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy under FASB ASC 820 are described below:
	Level 1	Quoted market prices in active markets for identical assets or liabilities;
	Level 2	Inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted market prices in markets that are not active or other inputs that are either directly or indirectly observable; and
	Level 3	Unobservable inputs using estimates and assumptions developed by the Company, which reflect those that a market participant would use.
The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of the observable inputs and minimize the use of unobservable inputs.
Recently Issued Accounting Standards
In July 2012, the FASB issued ASU 2012-02 “Intangibles-Goodwill and Other.” This guidance relates to testing indefinite-lived assets for impairment and will give entities an option not to calculate annually the fair value of an indefinite-lived intangible asset if the entity determines that it is not more likely than not that the asset is impaired. This type of assessment based on qualitative factors is similar to the goodwill impairment testing in ASU 2011-08. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. These new requirements are not expected to have a material impact on the Company’s consolidated financial statements.
In February 2013, the FASB issued ASU 2013-02 “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” This guidance requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income (loss) on the respective line items in net income (loss) if the amount being reclassified is required under US GAAP. For other amounts that are not required under US GAAP to be reclassified, in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under US GAAP that provide additional detail about those amounts. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. These new disclosure requirements are not expected to have a material impact on the Company’s consolidated financial statements.

ACQUISITION_OF_DREW_SCIENTIFIC

ACQUISITION OF DREW SCIENTIFIC, INC.	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	3  ACQUISITION OF DREW SCIENTIFIC, INC.
	Summary of Transaction
	On October 3, 2012, the Company acquired all of the issued and outstanding shares of capital stock of Drew Scientific from a subsidiary of Escalon Medical Corp. (“Escalon”) pursuant to a Stock Purchase Agreement between, among others, the Company and Escalon.
	The acquired businesses had been commonly known as the Escalon Clinical Diagnostics Business, which consisted of Drew Scientific (located in Waterbury, Connecticut, and Dallas, Texas), and its wholly-owned subsidiaries JAS Diagnostics, Inc. (“JAS Diagnostics”) ( located in Miami Lakes, Florida), and Drew Scientific Limited Co. (previously located in Barrow-in-Furness, United Kingdom). This group of companies develops and sells A1c and Hematology diagnostic instruments, reagents and chemistries. Drew Scientific provides instrumentation and consumables for physician office, small hospital and veterinary research laboratories. Drew Scientific also supplies the reagent and other consumable materials needed to operate the instruments. JAS Diagnostics manufactures a broad range of chemical reagents used in in vitro diagnostics tests.
	The purchase price paid by the Company for the all of the issued and outstanding shares of capital stock of Drew Scientific was $6,500,000, which was funded through the purchase, on October 3, 2012, by ERBA Mannheim from the Company of 8,666,667 shares of the Company’s common stock at a purchase price of $0.75 per share, for an aggregate purchase price of $6,500,000, pursuant to the terms of the Stock Purchase Agreement, as amended, between ERBA Mannheim and the Company.
	Accounting Treatment
	The purchase method of accounting was applied for the Drew Scientific business combination. The purchase price of $6,500,000 was allocated to net tangible and intangible assets based on their estimated fair values as of October 3, 2012, the acquisition date. The fair values determined by the Company’s management represent the prices that management believes would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
	The purpose of the acquisition was to integrate Drew Scientific’s manufacturing and distribution capabilities with the Company’s operations in an effort to achieve economies of scale and maximize the utilization of the Company’s assets and facilities. Assets acquired included certain intangible assets: customer relationships (to be amortized over 4.8 years), patents (to be amortized over a weighted average estimated useful life of approximately 7 years), and trademarks/tradenames (to be amortized over 10 years). The excess of the purchase price over the estimated fair values of the identifiable assets was recorded as goodwill primarily attributable to synergies expected to be gained from the integration of Drew Scientific into the Company’s existing operations. Transaction costs of approximately $211,000 associated with this acquisition were expensed as incurred through the consolidated statement of operations and comprehensive loss in each of the years ended December 31, 2013 and 2012.
	Below is a summary of assets acquired and liabilities assumed (rounded):
	Purchase price	$	6,500,000
	Fair value of assets acquired:
	Trade accounts receivable		1,211,000
	Inventories		2,093,000
	Prepaid and other current assets		140,000
	Property, plant and equipment		312,000
	Customer relationships		1,026,000
	Trademarks/tradenames		513,000
	Patents		309,000
	Other non-current assets		33,000
	Total fair value of assets acquired		5,637,000
	Fair value of liabilities assumed:
	Accounts payable		592,000
	Accrued expenses		844,000
	Deferred revenue		325,000
	Total fair value of liabilities assumed		1,761,000
	Fair value of net assets acquired		3,876,000
	Excess of purchase price over fair value of net assets acquired	$	2,624,000
	Pursuant to the Stock Purchase Agreement between the Company and Escalon, the Company executed an election under Internal Revenue Code Section 338(h)(10), on behalf of both the buyer(s) and seller(s) to treat the transaction as if it were a sale of assets for income tax purposes. The impact of this election has allowed the Company to step-up the basis of all acquired assets to fair market value in a fashion similar to the purchase accounting treatment described earlier for the financial accounting books of record.
	Prior to the October 3, 2012 acquisition date, the Company’s management decided to cease the operations of Drew Scientific Limited Co. located in the United Kingdom and Drew Scientific’s Dallas, Texas facility. As a result, the Company has accrued on the opening balance sheet as of October 3, 2012 estimated plant closing costs, including lease buy-out and severance costs, of $160,000 and $118,000, respectively. Regarding the Dallas, Texas facility, in May 2013, the Company’s management initially announced that the closing would be effective in late September 2013, but subsequently made a decision to keep the Dallas facility open for the foreseeable future. With respect to the United Kingdom facility, the closing was effective in late March 2013.
	Included in the accompanying 2012 consolidated statement of operations and comprehensive loss are Drew Scientific revenues of approximately $3,391,000 and net loss of approximately $238,000 since October 3, 2012, the acquisition date. Included in the accompanying 2013 consolidated statement of operations and comprehensive loss are Drew Scientific revenues of approximately $13,755,000 and net income of approximately $1,614,000. Unaudited pro forma information for the year ended December 31, 2012 of the Company as though the Company had completed the acquisition of Drew Scientific as of the beginning of the year would be approximately as follows: revenues of $29,264,000; net loss of $1,368,000; and net loss per share of $0.04. This unaudited pro forma financial information is presented for informational purposes only. The unaudited pro forma financial information may not necessarily reflect our future results of operations or what the results of operations would have been had the Company owned and operated Drew Scientific as of the beginning of the periods presented.

GOODWILL

GOODWILL	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	4  GOODWILL
	The FASB guidance for goodwill and other intangible assets uses the concept of reporting units. All acquisitions must be assigned to a reporting unit or units. Reporting units have been defined under the standards to be the same as or one level below an operating segment. The components of the carrying amount of goodwill as of December 31, 2013 and 2012 are as follows:
		Gross Carrying Amount		Accumulated Impairment			Net Book
							Value
	ImmunoVision	$	6,722,725	$	(5,852,435	)	$	870,290
	JAS Diagnostics	$	2,624,329		—			2,624,329
		$	9,347,054	$	(5,852,435	)	$	3,494,619

PRODUCT_LICENSE

PRODUCT LICENSE	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	5  PRODUCT LICENSE
	In September 2004, the Company entered into a license agreement with an Italian diagnostics company to obtain a perpetual, worldwide, royalty-free license of product technology used by the Italian diagnostics company. This licensed hepatitis product technology is existing technology, which the Italian diagnostics company had developed and successfully commercialized to manufacture hepatitis products sold by them and for which it had already received “CE Marking” approval from the European Union. Through the acquisition of this existing technology in its current form, the Company expects to be able to derive revenue from the manufacture and sale of new hepatitis products. In exchange for the Italian diagnostics company’s assistance in transferring the know-how of the manufacturing technology, the Company agreed to pay a total of 1,000,000 Euro in the form of four milestone payments upon the Italian diagnostics company’s achievement of certain enumerated performance objectives related to the transfer of such existing technology. Three of the four milestone payments, totaling 900,000 Euro, were made in prior years. During the year ended December 31, 2013, the balance of 100,000 Euro (equivalent to approximately $132,000) was offset against the accounts receivable owed to the Company from the Italian diagnostics company. In October 2011, the Company received “CE Marking” granting approval for the remaining products covered under the license agreement.
	During the fourth quarter of 2009, the Company determined that the carrying amount of the product license was in excess of its fair value and recorded a non-cash impairment charge to operations totaling $400,000, reducing the value of the product license to $282,936 as of December 31, 2009, from $682,936 as of December 31, 2008. Fair value was determined based upon the income approach, which estimates fair value based upon future discounted cash flows. Based upon this methodology, and utilizing significant assumptions in the income approach that included a forecasted cash flow period of five years and revenue and gross margin estimates beginning in 2012, estimated future cash flows generated by the technology granted by the product license was calculated using a discount rate of 23%, reflecting the Company’s best estimate of fair value.
	While the license is perpetual, the Company believes that the expected economic useful life of the license will be five years after the Company began to utilize the licensed technology for its intended purpose. Sales commenced in January 2013, at which time amortization of the license began. The Company amortized approximately $57,000 related to the license during the year ended December 31, 2013. The Company will amortize approximately $57,000 for each of the next four years related to the product license.

CONCENTRATION_OF_CREDIT_RISK

CONCENTRATION OF CREDIT RISK	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	6  CONCENTRATION OF CREDIT RISK
	The Company performs periodic credit evaluations of its customers’ financial condition and provides allowances for doubtful accounts as required. The Company maintains allowances for doubtful accounts, particularly in Italy where payment cycles are longer than in the United States, for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Additionally, the Company periodically receives payments based upon negotiated agreements with governmental regions in Italy, acting on behalf of hospitals located in the region, in satisfaction of previously outstanding accounts receivable balances.
	A substantial portion of the Company’s accounts receivable and revenues are derived from Delta Biologicals, the Company’s subsidiary located in Italy, and its operations may be affected by the recent fiscal and debt crisis the Italian government is facing. As of December 31, 2013 and 2012, Delta Biologicals’ accounts receivable, primarily due from Italian companies, were approximately $4,647,000 and $4,394,000, respectively. Amounts due from hospitals and laboratories controlled by the Italian government as of December 31, 2013 and 2012 were approximately $1,700,000 and $1,719,000, respectively, which accounted for approximately 24% and 27%, respectively, of the Company’s consolidated net accounts receivable. Delta Biologicals recognized revenues during the years ended December 31, 2013 and 2012 in the amount of approximately $5,138,000 and $5,032,000, respectively, which represented approximately 18% and 26%, respectively, of the Company’s consolidated net revenues.
	In recent years, the Italian government has been experiencing severe fiscal and debt crises and a recession, including its increasingly uncertain ability to service its sovereign debt obligations, caused in part by the declining global markets and economic conditions. Accordingly, the Company is subject to certain economic, business and, in particular, credit risk if its customers located in Italy, which are hospitals or laboratories controlled by the Italian government, do not pay amounts owed to the Company, extend payment cycles even further or ask the Company to accept a lower payment amount than is owed to the Company. The Company’s current allowances for doubtful accounts, although currently believed by management to be adequate, may not be adequate and the Company may be required to make additional allowances, which would adversely affect, and could materially adversely affect, the Company’s operating results in the period in which the determination or allowance is or was made. Any of these factors could materially and adversely affect the Company’s business, prospects, operating results, financial condition and cash flows in the near term.
	The Company’s cash management and investment policies restrict investments to low-risk, highly liquid securities, and the Company performs periodic evaluations of the credit standing of the financial institutions with which it deals. A significant portion of the Company’s cash and cash equivalents are presently held at one international securities brokerage firm. Accordingly, the Company is subject to credit risk of approximately $1,704,000 if this brokerage firm is unable to repay the balance in the account or deliver the Company’s securities or if the brokerage firm should become bankrupt or otherwise insolvent. The Company’s cash balances exceed federally insured limits by approximately $954,020 as of December 31, 2013.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	7  INCOME TAXES
	The provision (benefit) for income taxes consists of the following for the years ended December 31, 2013 and 2012:
		2013			2012
	Current:
	Domestic	$	—		$	10,500
	Foreign		50,266			30,856
	Deferred:
	Domestic		68,788			80,689
	Total	$	119,054		$	122,045
	The components of income (loss) before income taxes are as follows for the years ended December 31, 2013 and 2012:
		2013			2012
	Domestic	$	1,056,504		$	(948,194	)
	Foreign		(261,622	)		(483,117	)
	Total	$	794,882		$	(1,431,311	)
	The significant components of the net deferred income tax asset balances are as follows as of December 31, 2013 and 2012:
		2013			2012
	Current:
	Accounts receivable allowances	$	301,628		$	275,413
	Reserves and accruals		248,119			384,065
	Capitalized inventory costs		102,742			116,897
	Other		608			608
	Valuation allowance		(653,097	)		(776,983	)
	Deferred income taxes		—			—
	Long-term:
	Depreciation and basis differences on tangible and intangible assets		396,524			305,052
	Stock based compensation		410,987			359,397
	Other		(53,372	)		20,433
	Foreign net operating losses		1,005,901			931,213
	Domestic net operating losses		7,063.33			7,411,884
	Valuation allowance		(8,823,368	)		(9,027,979	)
	Net deferred tax asset	$	—		$	—
	The net deferred income tax liability balance consists of tax deductible goodwill of $578,153 and $509,365, as of December 31, 2013 and 2012, respectively.
	The Company’s deferred tax assets or liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability from period to period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, then a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance would be included in the provision for deferred income taxes in the period of change.
	The Company has established a full valuation allowance on its net domestic deferred tax assets, which are primarily comprised of net operating loss carryforwards. Accordingly, as of December 31, 2013 and 2012, the Company had no net domestic deferred tax assets. As of December 31, 2013 and 2012, the Company had net deferred tax liabilities of $578,153 and $509,365, respectively, relating to tax deductible goodwill which is not expected to reverse in the foreseeable future. Additionally, as of December 31, 2013 and 2012, the Company also had no net foreign deferred tax asset, as a full valuation allowance was provided. Future changes in the estimated net realizable value of the deferred tax assets or deferred tax liabilities could cause the provision for income taxes to vary significantly from period to period.
	A reconciliation of the difference between the expected provision (benefit) for income taxes using the statutory U.S. Federal tax rate and the Company’s actual provision (benefit) is as follows for the years ended December 31, 2013 and 2012:
		2013			2012
	Provision (benefit) for income taxes at U.S. Federal statutory	$	298,591		$	(500,959	)
	rate of 35%
						—
	Change in valuation allowance (excluding portion relating to stock options)		(328,498	)		239,458
	Foreign tax rate differential		63,480			293,028
	Global permanent differences		85,481			90,518
	Provision (benefit) for income taxes	$	119,054		$	122,045
	The Company’s income tax provision or benefit for the years ended December 31, 2013 and 2012 was different from the amount computed on the loss before provision (benefit) for income taxes at the statutory rate of 35% primarily due to changes in the valuation allowance, foreign tax rate differential and global permanent differences. The Company recorded a net income tax provision of $119,054 during the year ended December 31, 2013 and a net income tax provision of $122,045 during 2012.
	Domestic net operating losses generated by the Company total $18,110,000 as of December 31, 2013 and are subject to any applicable limitations as described below. The net operating losses included in the domestic net deferred tax asset will begin to expire in 2022. Under Section 382 of the Internal Revenue Code, the Company’s use of its net operating loss carryforwards will be limited in the future as a result of the September 1, 2010 acquisition by ERBA Mannheim of the approximately 72.4% of the then outstanding shares of the Company’s common stock previously owned by the Debregeas-Kennedy Group. As a result of that acquisition, the Company’s ability to utilize net operating loss carryforwards to offset any future taxable income is currently limited to approximately $825,000 per year, plus both any limitation unused since the acquisition and any unused net operating losses generated after the September 1, 2010 acquisition date. The amount of the annual limitation will be adjusted upwards for any recognized built-in gains on certain assets sold during the five year period commencing with the ownership change. The limitations of these net operating loss carryforwards did not impact the Company’s results for the years ended December 31, 2013 or 2012.
	United States income taxes have not been provided on undistributed earnings of foreign subsidiaries, as such earnings are being retained indefinitely by such subsidiaries for reinvestment. The distribution of these earnings would first reduce the domestic valuation allowance before resulting in additional United States income taxes.
	As of December 31, 2013, the Company’s Federal income tax returns for the years 2010 through 2013 and, with respect to foreign operations, the Italian income tax returns for 2009 through 2013 remain subject to examination. Although the Company’s Federal income tax returns from 2002 through 2009 are not generally open to examination, the Company remains subject to adjustments in these years to the extent of the net operating losses being carried forward from those years. No examinations are currently in progress with any taxing authorities.
	Regarding the accounting for uncertainties in income taxes, the Company recognizes the financial statement liability of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest liability that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. As of December 31, 2013 and 2012, the Company had no unrecognized tax liabilities. If uncertain tax positions had been recorded, then the Company would recognize interest and penalties related to uncertain tax positions in income tax expense.
	Under the Internal Revenue Code, pursuant to the Health Care and Education Reconciliation Act of 2010 and in conjunction with the Patient Protection and Affordable Care Act, a new excise tax has been imposed on the sale of certain medical devices beginning on January 1, 2013. This medical device excise tax has been imposed on manufacturers, importers and producers of certain devices listed with the FDA. During the year ended December 31, 2013, the Company accrued approximately $185,000 in connection with its obligation to pay the new medical device excise tax.

EMPLOYEE_BENEFIT_PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	8  EMPLOYEE BENEFIT PLANS
	The Company has a 401(k) employee savings plan which allows for pre-tax employee payroll contributions and discretionary employer matching contributions. The Company did not make any matching contributions during the year ended December 31, 2013. Matching contributions during the year ended December 31, 2012 were $112,970.
	Drew Scientific adopted a 401(k) retirement plan for Drew Scientific’s United States employees. Employer contributions are discretionary; no employer contributions have been made to the 401(k) retirement plan since Drew Scientific was acquired by Escalon on July 23, 2004. This plan has continued subsequent to October 3, 2012, the date of the acquisition of Drew Scientific by the Company; during the year ended December 31, 2013, this plan was merged into the Company’s 401(k) employee savings plan.
	Drew Scientific also had a defined contribution retirement plan. This plan had continued subsequent to October 3, 2012 and was available only to Drew Scientific’s United Kingdom employees. Employer contributions since the date of acquisition through December 31, 2012 were not material; the plan was terminated in February 2013 as part of the closure of the United Kingdom facility.

ACCRUED_EXPENSES_AND_OTHER_LON

ACCRUED EXPENSES AND OTHER LONG-TERM LIABILITIES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]	'
	9  ACCRUED EXPENSES AND OTHER LONG-TERM LIABILITIES
	Accrued expenses consist of the following as of December 31, 2013 and 2012:
		2013		2012
	Payroll costs	$	645,943	$	892,564
	Taxes, primarily VAT		800,756		572,095
	Professional fees		583,991		277,416
	Royalties		65,270		82,562
	Accrued acquisition costs		—		70,004
	Accrued plant closing costs		172,632		274,888
	Deferred revenue		249,159		406,840
	Other		376,679		233,078
	Balance as of December 31	$	2,894,430	$	2,809,447
	Other long-term liabilities of $1,027,425 as of December 31, 2013, and $993,980 as of December 31, 2012, consist primarily of Italian employee leaving indemnity. Italian law provides that each employee is entitled to receive a payment upon severance of employment. The amounts vest immediately and are adjusted for inflation.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
	10  SHAREHOLDERS’ EQUITY
	Common Stock
	On March 14, 2001, b2bstores.com Inc. (now known as ERBA Diagnostics, Inc.), IVAX Corporation and the pre-merger IVAX Diagnostics consummated a merger of the pre-merger IVAX Diagnostics into b2bstores.com pursuant to which all of the issued and outstanding shares of the pre-merger IVAX Diagnostics were converted into 20,000,000 shares of b2bstores.com stock and b2bstores.com’s name was changed to “IVAX Diagnostics, Inc.”
	Concurrent with the approval of the merger between b2bstores.com and the pre-merger IVAX Diagnostics, the Company amended its certificate of incorporation to increase the number of shares of authorized common stock from 25,000,000 to 50,000,000.
	On June 10, 2011, the Company amended its certificate of incorporation to increase the number of shares of authorized common stock from 50,000,000 to 100,000,000.
	During the years ended December 31, 2013 and 2012, the Company entered into various agreements and transactions with its majority stockholder. See Note 13, Related Party Transactions.
	Share Repurchase Program
	In 2002, the Company’s Board of Directors approved a program to repurchase up to 2,000,000 shares of the Company’s publicly held common stock. During the years ended December 31, 2013 and 2012, the Company did not repurchase any shares of its common stock. The total number of shares of common stock repurchased by the Company since the inception of its repurchase program is 1,184,573.
	Equity Incentive Plans
	On June 3, 2009, the Company’s stockholders approved the Company’s 2009 Equity Incentive Plan (the “2009 Plan”), which the Company’s Board of Directors had approved and recommended. The 2009 Plan is the successor plan to both of the Company’s previously adopted equity incentive compensation plans — the 1999 Performance Equity Plan (the “Performance Plan”) and the 1999 Stock Option Plan (the “1999 Plan,” and together with the Performance Plan, collectively, the “Prior Plans”). As a result of the approval of the 2009 Plan, the Company will not make any future grants under the Prior Plans. In addition to the 1,561,072 shares of the Company’s common stock that remained available for grant from the Prior Plans prior to June 3, 2009, an additional 2,000,000 shares of common stock were authorized for grant under the 2009 Plan.
	The Company’s Performance Plan was created on September 30, 1999 upon approval by the Board of Directors and stockholders of b2bstores.com. The Performance Plan authorized the grant of up to 2,000,000 shares of common stock of the Company to key employees, officers, directors and consultants. As a result of the approval of the 2009 Plan, the Company will not grant any additional awards under the Performance Plan.
	Options granted under these option plans were granted at an option exercise price equal to or greater than the closing market value of the stock on the date of the grant and with vesting, primarily for Company employees, ranging from all at once to equal annual amounts over a four year period, and, for non-employee directors, immediately. The options generally have a term of 10 years. The following table summarizes the stock option activity (both outstanding and exercisable) as of December 31, 2013 and 2012 and changes during the years ended December 31, 2013 and 2012 under the Performance Plan and the 2009 Plan:
		Number of Shares		Weighted Average Exercise Price
	Balance as of December 31, 2011		1,020,870	$	1.36
	Granted		100,000	$	0.55
	Balance as of December 31, 2012		1,120,870	$	1.28
	Granted		100,000	$	1.52
	Forfeited		50,000	$	0.65
	Balance as of December 31, 2013		1,170,870	$	1.33
		Options Outstanding and Exercisable
	Range of Exercise Prices	Number of Shares		Weighted Average Remaining Contractual Life		Weighted
				(In Years)		Average Price
	$0.00 – $0.50		100,000		5.3	$	0.48
	$0.51 – $0.75		445,870		6.1	$	0.58
	$0.76 – $1.00		175,000		4.6	$	0.96
	$1.01 – $1.50		100,000		4.7	$	1.2
	$1.51 – $3.00		200,000		6.2	$	1.54
	$3.01 – $6.00		150,000		1.5	$	4.37
			1,170,870		5.3	$	1.33
	The aggregate intrinsic value of options outstanding and exercisable was $1,884,000 and $179,000 as of December 31, 2013 and 2012, respectively. As of December 31, 2013 and 2012, all outstanding options were vested and therefore there was no unrecognized compensation cost. No windfall tax benefits were recognized during the years ended December 31, 2013 or 2012.

SEGMENT_INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	11  SEGMENT INFORMATION
	The Company’s management reviews financial information, allocates resources and manages its business by geographic region. The domestic region, which includes corporate expenditures, contains the Company’s subsidiaries in the United States. The domestic region includes the operations of Drew Scientific and its subsidiaries from and after the acquisition date of October 3, 2012; see Note 3, Acquisition of Drew Scientific, Inc. The European region contains Delta Biologicals, the Company’s subsidiary located in Italy, and, from and after the acquisition date of October 3, 2012 and until late March 2013, Drew Scientific Limited Co. The information provided is based on internal reports and was developed and utilized by management to track trends and changes in the results of the regions. The information, including the allocations of expense and overhead, was calculated based on a management approach and may not reflect the actual economic costs, contributions or results of operations of the regions as stand-alone businesses. If a different basis of presentation or allocation were utilized, the relative contributions of the regions might differ but the relative trends would, in management’s view, likely not be materially impacted. The table below sets forth net revenues, loss from operations, total assets and goodwill by region for the years ended December 31, 2013 and 2012:
		Domestic			European			Eliminations			Total
	December 31, 2013:
	External net sales	$	23,117,502		$	5,137,815		$	—		$	28,255,317
	Intercompany sales		488,764			19,615			(508,379	)		—
	Net revenue	$	23,606,266		$	5,157,430			($508,379	)	$	28,255,317
	Income (loss) from operations	$	1,137,515			($100,790	)	$	—		$	1,036,725
	Assets	$	40,287,271		$	6,047,420			($20,460,225	)	$	25,874,466
	Goodwill	$	3,494,619		$	—		$	—		$	3,494,619
	December 31, 2012:
	External net sales	$	14,316,923		$	5,032,081		$	—		$	19,349,004
	Intercompany sales		575,210			115,141			(690,351	)		—
	Net revenue	$	14,892,133		$	5,147,222			($690,351	)	$	19,349,004
	(Loss) from operations		($821,019	)		($382,142	)	$	—			($1,203,161	)
	Assets	$	38,785,080		$	6,163,472			($20,394,784	)	$	24,553,768
	Goodwill	$	3,494,619		$	—		$	—		$	3,494,619

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	12  COMMITMENTS AND CONTINGENCIES
	Leases
	As of December 31, 2013, the Company is a lessee under non-cancelable leases with third parties. These arrangements are described below.
	ImmunoVision has a lease agreement, which commenced on August 1, 2000 and was amended in July 2012, for office and warehouse space in Bentonville, Arkansas. The amended lease expires on July 31, 2016 and provides for annual rent expense of $72,000 through July 31, 2014 and $73,440 through July 31, 2016.
	Delta Biologicals has a lease agreement, which commenced on September 1, 2011, for office and warehouse space in Pomezia, Italy. The lease expires on August 31, 2017 and provides for annual rent expense of Euro 120,000 (equivalent to approximately $159,000 as of December 31, 2013). The lease also provides for one six-year renewal option.
	JAS Diagnostics has a lease agreement, which commenced on January 1, 2010 and was amended in March 2013, for its corporate headquarters and warehouse facilities in Miami Lakes, Florida. The amended lease expires on December 31, 2019 and provides for annual rent expense for the existing space and two expansion premises, as follows for each of the succeeding five years: 2014, $391,150; 2015, $401,280; 2016, $417,657; 2017, $434,024; and 2018, $451,386. The amended lease also provides for one five-year renewal option at a market rental rate.
	Drew Scientific also had a lease agreement, which commenced on December 15, 2012, for office and warehouse space in Waterbury, Connecticut. The lease expired on December 31, 2013. Drew Scientific continues to lease the space on a month to month basis.
	The Company has various equipment and vehicle operating leases with third parties that expire from March 2012 through February 2017.
	Aggregate rent expense under all operating leases for the years ended December 31, 2013 and 2012 totaled approximately $735,000 and $496,000, respectively.
	The future minimum lease payments for the next five years under these and other non-cancelable operating leases with initial or remaining terms of one year or more as of December 31, 2013 are as follows:
	2014	$	822,000
	2015		710,000
	2016		650,000
	2017		590,000
	2018		451,000
	Total minimum lease payments	$	3,223,000
	During the year ended December 31, 2010, the Company entered into a 36-month capital lease agreement with the same financing company for bottling equipment for its production facility in Miami, Florida. The terms of the lease agreement require that the Company make equal monthly payments and grant the Company the option to purchase the equipment at the end of the lease for an amount not to exceed 22% of the original price for which the financing company purchased such equipment. The asset and liability under this capital lease are recorded at the lower of the present value of the minimum lease payments or the fair value of the asset. The asset is depreciated over its estimated productive life (cost of $222,000, net of accumulated depreciation of $91,000). Depreciation of $28,000 in the year ended December 31, 2013 and $25,000 in the year ended December 31, 2012 was included in cost of sales. The lease agreement expired in March 2013. The Company continued to lease the equipment upon the maturity of the lease agreement under an operating lease for monthly lease payments of approximately $7,000. The Company will retain ownership of the equipment in August 2014. There was no capital lease obligation as of December 31, 2013. The capital lease obligation as of December 31, 2012 was approximately $22,000 and was included in the current capital lease obligations in the 2012 consolidated balance sheet. Interest expense for the years ended December 31, 2013 and 2012 was approximately $15,000 in both of the years.
	Litigation, Claims and Assessments
	The Company is involved in various legal claims and actions and regulatory matters, and other notices and demand proceedings arising in the ordinary course of business. While it is not possible to predict or determine the outcome of these proceedings, in the opinion of management, based on a review with legal counsel, any losses resulting from such legal proceedings would not have a material adverse impact on the financial position, results of operations or cash flows of the Company.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	13  RELATED PARTY TRANSACTIONS
	Certain Relationships and Related Transactions
	During the years ended December 31, 2013 and 2012, the Company sold products to Transasia and a subsidiary of ERBA Mannheim for a total amount of approximately $606,000 and approximately $501,000 respectively.
	During 2011, Delta Biologicals entered into a contract research and development agreement with ERBA Mannheim, as amended, for a total of Euro 754,700, pursuant to which ERBA Mannheim has agreed to pay the subsidiary a total amount of Euro 133,000 (equivalent to approximately $186,000) during the year ended December 31, 2011 and an additional Euro 621,700 (equivalent to approximately $799,000) during the year ended December 31, 2012 for the results of certain research and development.
	Delta Biologicals incurred additional expenses related to the research and development mentioned above which were billed to ERBA Mannheim for reimbursement. For the years ended December 31, 2013 and 2012, contract research and development revenue under the above mentioned agreement approximated Euro 675,000 (equivalent to approximately $896,000) and Euro 650,000 (equivalent to approximately $836,000), respectively.
	The Company had net accounts receivable from ERBA Mannheim and Transasia of $1,835,000 and $644,000 as of December 31, 2013 and 2012, respectively, related to the above transactions and receivables from the sale of products and the reimbursement of various expenditures incurred on behalf of ERBA Mannheim.
	On June 15, 2012, the Company entered into a use of name license agreement with ERBA Mannheim granting a royalty-free, non-exclusive license to use the name “ERBA” for an annual fee of one dollar. The license agreement will be terminated upon the earlier of (a) the transfer by ERBA Mannheim to the Company of all of ERBA Mannheim’s rights, title and interest in and to the use of the name and any stylized logos or marks associated with the name (the date that such transfer becomes effective, the “Transfer Date”) and (b) such time, if any, as ERBA Mannheim no longer owns, directly or indirectly, shares of the Company’s common stock representing more than 50% of the issued and outstanding shares of such stock (the “Share Threshold Date”). Furthermore, ERBA Mannheim may terminate the license agreement at any time prior to the earlier of the Transfer Date and the Share Threshold Date: (a) upon providing the Company 180 days prior written notice of its intent to terminate and the date upon which the license agreement shall terminate; or (b) upon providing the Company 30 days prior written notice of any breach of the license agreement by the Company, which breach remains uncured at the end of such 30 day period.
	In December 2012, JAS Diagnostics entered into a Research and Development Outsourcing Agreement with Erba Diagnostics France SARL (“Erba Diagnostics France”), pursuant to which JAS Diagnostics has agreed to pay Erba Diagnostics France a total amount of Euro 350,000 (equivalent to approximately $462,500) plus additional material costs, in seven monthly installments of Euro 50,000 from December 2012 through June 2013, for certain research and development endeavors. The initial payment of Euro 50,000 (equivalent to approximately $64,900) is included in research and development expenses in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2012.
	On July 24, 2013, JAS Diagnostics and Erba Diagnostics France mutually terminated the agreement above and Erba Diagnostics France agreed to refund to JAS Diagnostics all amounts paid under the agreement within 90 days. The Company continued to pay for the research and development costs through October 2013. The Company incurred total research and development costs of approximately $913,000, all of which were reimbursed by Erba Diagnostics France during the year ended December 31, 2013. The reimbursed research and development costs were recognized as a reduction to research and development expense included in the 2013 consolidated statement of operations.
	Common Stock and Equity Transactions
	The Company entered into the Stock Purchase Agreement with ERBA Mannheim, on April 8, 2011, pursuant to which the Company agreed to sell and issue to ERBA Mannheim an aggregate of 20,000,000 shares of the Company’s common stock for an aggregate purchase price of $15,000,000, or $0.75 per share of the Company’s common stock, and warrants to purchase an additional 20,000,000 shares of the Company’s common stock. The consummation of the investment contemplated by the Stock Purchase Agreement was subject to, among other things, the approval of holders of at least 66- 2/3% of the issued and outstanding shares of the Company’s common stock (excluding any shares beneficially owned, directly or indirectly, by ERBA Mannheim). At the 2011 Annual Meeting of Stockholders held on June 10, 2011, the required approval of the Company’s stockholders was achieved.
	On June 30, 2011, ERBA Mannheim paid the Company $5,000,000 in order to consummate the initial transactions contemplated by the Stock Purchase Agreement (the “Initial Closing”). As a result, at the Initial Closing, the Company issued to ERBA Mannheim 6,666,667 shares of common stock and, in connection with the consummation of the initial transactions contemplated by the Stock Purchase Agreement, a warrant to purchase an additional 20,000,000 shares of common stock (the “Warrant”). After giving effect to transaction costs of $399,700 relating to the Stock Purchase Agreement, the Company received net proceeds of $4,600,300 at the consummation of the initial transactions contemplated by the Stock Purchase Agreement. The Warrant has a five year term and an exercise price per share of the Company’s common stock of $0.75 and is exercisable only to the extent that shares of the Company’s common stock have been purchased under the Stock Purchase Agreement.
	On April 16, 2012, ERBA Mannheim exercised, in part, the Warrant by paying an aggregate exercise price of $450,000 and, in connection therewith, the Company issued to ERBA Mannheim 600,000 shares of the Company’s common stock. A total of 19,400,000 warrants remain unexercised as of December 31, 2013 and 2012. As of December 31, 2013 and 2012, the Warrant was exercisable for 14,733,334 shares of the Company’s common stock.
	Pursuant to amendments to the Stock Purchase Agreement on December 29, 2011 and October 3, 2012, each of which was unanimously approved by the independent directors on the Board of Directors, the Company and ERBA Mannheim agreed that the Company would sell and issue to ERBA Mannheim, and ERBA Mannheim would purchase from the Company, 8,666,667 shares of common stock at the second closing of the transactions contemplated by the Stock Purchase Agreement (the “Second Closing”) for an aggregate purchase price of $6,500,000, or $0.75 per share, and 4,666,666 shares of common stock at the final closing of the transactions contemplated by the Stock Purchase Agreement (the “Final Closing”) for an aggregate purchase price of $3,500,000, or $0.75 per share. In addition, pursuant to the amendments to the Stock Purchase Agreement, the Company and ERBA Mannheim agreed to hold the Second Closing as promptly as practicable on or after October 3, 2012 and to hold the Final Closing on the date that is 60 days after the date on which a majority of the independent directors on the Board of Directors determines by vote or written consent that such issuance, sale and purchase shall occur and causes notice thereof to be delivered to ERBA Mannheim.
	The Second Closing was held on October 3, 2012, at which time ERBA Mannheim paid the $6,500,000 aggregate purchase price to the Company, and, in connection therewith, the Company issued to ERBA Mannheim 8,666,667 shares of the Company’s common stock. As described in Note 3, Acquisition of Drew Scientific, Inc., the Company used all of the proceeds of the Second Closing to consummate the acquisition of Drew Scientific.
	Other Transactions
	During the years ended December 31, 2013 and 2012, ImmunoVision paid $10,000 and $24,000, respectively, to John B. Harley, M.D., Ph.D., a member of the Board of Directors, under that certain oral consulting agreement between Dr. Harley, and ImmunoVision pursuant to which Dr. Harley was paid $2,000 per month in consideration for his provision of technical guidance and business assistance to the subsidiary on an as-needed basis. The oral consulting agreement ended in May 2013.
	Pursuant to a license agreement between the Company and Dr. Harley, he has granted an exclusive worldwide license to the Company for certain patents, rights and technology relating to monoclonal antibodies against autoimmune RNA proteins developed by him in exchange for specified royalty payments, including an annual minimum royalty of $10,000 for each licensed product utilized by the Company. For the years ended December 31, 2013 and 2012, the Company paid $10,000 under such royalty agreement.
	The amounts paid to Dr. Harley were in addition to the amounts he received for his service as member of the Company’s Board of Directors and the committees of the Board of Directors on which he served.

REVOLVING_LINE_OF_CREDIT

REVOLVING LINE OF CREDIT	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	14  REVOLVING LINE OF CREDIT
	On June 10, 2011, Diamedix entered into a Loan Agreement with City National Bank of Florida, which provided for a secured, revolving credit facility of up to $975,000 (the “Old Line of Credit”). As described below, the Company closed down the Old Line of Credit and the Company entered into a new loan agreement with Citibank, N.A. Amounts outstanding under the Old Line of Credit accrued interest at an annual rate equal to the 30-day LIBOR plus 4.00%, and the loan was to become due and payable on June 10, 2013.
	Closing costs and other transaction costs aggregating $101,482 were incurred in 2011 related to the loan agreement and the Old Line of Credit. These costs have been classified as debt issuance costs on the accompanying consolidated balance sheets (included in other current assets) were amortized over the 24-month term of the Old Line of Credit commencing in June 2011. Amortization expense for the year ended December 31, 2012 was $50,736. In connection with establishing the New Line of Credit, as discussed below, Diamedix contemporaneously closed the Old Line of Credit with City National Bank of Florida. The payoff amount at closing was $975,000.
	On March 1, 2013, the Company entered into that certain Business Loan Agreement and that certain Promissory Note with Citibank, N.A. (“Citibank”), which provides for a secured, revolving credit facility of up to $2,000,000 (the “New Line of Credit”). Amounts outstanding under the New Line of Credit will accrue interest at an annual rate equal to the 30-day LIBOR plus 1.75% (1.92% at December 31, 2013) and will become due and payable on December 31, 2014, subject to acceleration upon the occurrence of certain specified events of default that the Company believes are customary for transactions of this type. Pursuant to the business loan agreement, the Company will be subject to certain specified positive and negative covenants (including, without limitation, the requirements to maintain a specified capital base of not less than $8,500,000 and a specified leverage ratio, as defined, of not less than 2.0-to-1.0) that the Company believes are customary for transactions of this type.
	Amounts outstanding under the New Line of Credit have been collateralized by all of the assets of the Company and its wholly-owned subsidiaries located in the United States — Diamedix, ImmunoVision, and Drew Scientific. In addition, each of Diamedix, ImmunoVision and Drew Scientific has guaranteed the repayment of amounts drawn on the New Line of Credit. Further, Transasia, the indirect parent company of the Company, has also guaranteed the repayment of amounts drawn on the New Line of Credit.
	As of December 31, 2013, approximately $1,905,000 was outstanding under the New Line of Credit.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The accompanying consolidated financial statements are presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include the accounts of ERBA Diagnostics, Inc. and its wholly-owned subsidiaries Diamedix Corporation (“Diamedix”), ImmunoVision, Inc. (“ImmunoVision”) and Delta Biologicals, S.r.l. (“Delta Biologicals”) and, from and after the acquisition date of October 3, 2012, Drew Scientific, Inc. and its subsidiaries (“Drew Scientific”) (as more fully described in Note 3, Acquisition of Drew Scientific, Inc.). All significant intra-entity balances and transactions have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current year’s presentation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, at the date of and for the period of the consolidated financial statements. The Company’s actual results in subsequent periods may differ from the estimates and judgments used in the preparation of the accompanying consolidated financial statements. Significant estimates include the allowance for doubtful accounts, inventories, intangible assets, income and other tax accruals, stock based compensation, the computation of fair-value measurements related to the acquisition of Drew Scientific, the realization of long-lived assets and contingencies and litigation.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers certain short-term investments in money market accounts with original maturities of three months or less to be cash equivalents.
Accounts Receivable And Allowance For Doubtful Accounts [Policy Text Block]	'
	Accounts Receivable and Allowance for Doubtful Accounts
	The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained, particularly in Italy where payment cycles are longer than in the United States and in some instances may take in excess of a year to collect, for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been followed in accordance with the Company’s policies. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.
	The Company periodically receives payments based upon negotiated agreements with governmental regions in Italy, acting on behalf of hospitals located in the region, in satisfaction of previously outstanding accounts receivable balances. The Company may have anticipated collection of these amounts through a payment as described above and, therefore, not provided an allowance for doubtful accounts for these amounts. Future payments by governmental regions in Italy are possible and, as a result, the Company may consider the potential receipt of those payments in determining its allowance for doubtful accounts. If contemplated payments are not received when expected or at all, or if negotiated agreements are not complied with in a timely manner or cancelled, then the Company may provide additional allowances for doubtful accounts.
	The allowance for doubtful accounts was $1,064,739 and $995,662 as of December 31, 2013 and 2012, respectively, and activity for the years then ended was as follows:
			2013		2012
	Balance as of January 1		$	995,662	$	716,599
	Provision			39,559		625,935
	Write-offs			—		(361,229	)
	Effects of changes in foreign exchange rates			29,518		14,357
	Balance as of December 31		$	1,064,739	$	995,662
Inventory, Policy [Policy Text Block]	'
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market. Components of inventory cost include materials, labor and manufacturing overhead. In evaluating whether inventory is stated at the lower of cost or market, management considers such factors as the amount of inventory on hand, estimated time required to sell such inventory, remaining shelf life and current market conditions. Inventory costs associated with marketed products are capitalized, as are certain unapproved products prior to regulatory approval and product launch, based on management’s judgment of probable future economic benefit which includes an assessment of probability of future commercial use and net realizable value. With respect to instrumentation products, the Company purchases instrument parts and, in some cases, manufactures instrument components in preparation for the commercial launch of the instrument in amounts sufficient to support forecasted initial market demand. Inventory is not capitalized unless the product or instrument is considered to have a high probability of receiving regulatory approval. The Company may make this determination prior to its submission to the United States Food and Drug Administration (“FDA”) of a 510(k) application or other required regulatory submission. In determining probability, if the Company is aware of any specific risks or contingencies that are likely to adversely impact the expected regulatory approval process, then it would not capitalize the related inventory but would instead expense it as incurred. Additionally, the Company’s estimates of future instrumentation and diagnostic kit product demand, or judgment of probable future economic benefit, may prove to be inaccurate, in which case any resulting adjustments to the value of inventory would be recognized at the time of such determination. Reserves are provided as appropriate to reduce excess or obsolete inventories to the lower of cost or market. Inventories, net consist of the following as of December 31, 2013 and 2012:
			2013		2012
	Raw materials		$	3,123,380	$	1,712,199
	Work-in-process			624,454		664,880
	Finished goods			2,746,339		3,461,071
	Total inventories, net		$	6,494,173	$	5,838,150
	The Company regularly reviews inventory quantities on hand, which include components for current or future versions of products and instrumentation. If necessary, the Company records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements, as well as based upon the status of a product within the regulatory approval process. In accordance with the Company’s inventory accounting policy, the Company’s inventory balance at times includes components for current or future versions of products and instrumentation. Inventory reserves were approximately $1,129,000 and $816,000 as of December 31, 2013 and December 31, 2012, respectively.
	Our inventory balance as of December 31, 2012 included approximately $100,000 of inventory relating to our hepatitis product, substantially all of which has a shelf life exceeding five years, for which we obtained “CE Marking” approval in the European Union during 2011 and for which we have begun selling in certain markets. As a result of sales in 2013, the inventory balance has been depleted as of December 31, 2013.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful lives of the assets as follows:
			Years
	Buildings and improvements			5 – 20
	Machinery and equipment			3 – 10
	Furniture and fixtures			3 – 10
	Costs of major additions and improvements are capitalized and expenditures for maintenance and repairs which do not extend the life of the assets are expensed. Upon sale or disposition of property, plant and equipment, the cost and related accumulated depreciation is eliminated from the accounts and any resulting gain or loss is credited or charged to operations.
	Depreciation expense was $393,462 and $326,917 during the years ended December 31, 2013 and 2012, respectively.
Lease, Policy [Policy Text Block]	'
	Equipment on Lease, Net
	The cost of the Company’s owned instruments, which are placed under reagent rental programs at customer facilities for testing and usage of the Company’s products (see Note 2, Summary of Significant Accounting Policies, below under the heading Revenue Recognition), less accumulated amortization, consists of the following as of December 31, 2013 and 2012:
			2013		2012
	Equipment on lease, at cost		$	6,773,917	$	6,666,122
	Less accumulated amortization			6,187,132		6,080,801
			$	586,785	$	585,321
	Equipment on lease is typically amortized over three or five years. Amortization expense was $214,237 and $172,175 for the years ended December 31, 2013 and 2012, respectively.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible Assets
	Intangible assets relate to the acquisition of Drew Scientific (as more fully described in Note 3, Acquisition of Drew Scientific, Inc.) and consist of the following as of December 31, 2013 and 2012:
			Estimated Useful Life (Years)		As of December 31, 2013							As of December 31, 2012
					Gross			Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
					Amount					Amount		Amount				Amount
	Customer relationships			4.8	$	1,026,532		$	266,957	$	759,575	$	1,026,532	$	53,096	$	973,436
	Trademarks/ tradenames			10		512,701			64,087		448,614		512,701		12,817		499,884
	Patents			7		309,057			53,168		255,889		309,057		9,972		299,085
	Lease rights			2		47,140			31,067		16,073		47,140		7,497		39,643
					$	1,895,430		$	415,279	$	1,480,151	$	1,895,430	$	83,382	$	1,812,048
	Amortization expense is computed principally on a straight-line basis and for the next five years approximates:
	Years Ending December 31,
	2014		$	324,000
	2015			306,000
	2016			306,000
	2017			216,000
	2018			94,000
			$	1,228,000
	Amortization expense related to the acquired intangible assets for the years ended December 31, 2013 and 2012 amounted to $331,897 and $83,382, respectively.
Long Lived Assets Including Goodwill [Policy Text Block]	'
	Long Lived Assets, Including Goodwill
	Goodwill is attributed to the acquisitions of ImmunoVision and Drew Scientific and represents the excess of the cost over the fair value of nets assets acquired. The Company tests goodwill for possible impairment on an annual basis and at any other time events occur or circumstances indicate that the carrying amount of goodwill may be impaired. The first step required in the impairment analysis consists of a comparison of the fair value of the reporting unit with its carrying amount, including the goodwill.
	For the annual test of its remaining goodwill at ImmunoVision, the Company determined fair value primarily based upon the income approach, which estimates the fair value based on the future discounted cash flows, rather than the market approach, which estimates the fair value based on market prices of comparable companies. The Company believes the income approach is more appropriate to determine the fair value at ImmunoVision and should therefore be more heavily weighted due to the fact that similar public companies comparable to ImmunoVision are difficult to identify and current market conditions are in a period of volatility with wide ranging multiples. Based upon this methodology, and utilizing significant assumptions in the income approach that included a forecasted cash flow period of five years, long-term annual growth rates of 3% for both years and a discount rate of 19% and 20% for 2013 and 2102, respectively, no impairment was recorded for the years ended December 31, 2013 or 2012.
	The goodwill of Drew Scientific was also subjected to the annual testing for impairment and its value was determined by the Company with similar significant reliance on the income approach. This approach utilized significant assumptions including a forecasted cash flow period of five years, a long-term annual growth rate 3% and a discount rate of 19%. The market approach was not considered to be as reliable as the income approach due to the difficulty of identifying similar publicly traded companies comparable to Drew Scientific and the stock price volatility in the industry. The Company determined that the income approach is more appropriate, and, based upon the results of the Company’s analysis, no impairment was recorded during the year ended December 31, 2013.
	The Company reviews its long-lived assets for impairment, including intangible assets and fixed assets that are held and used in its operations, whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If such an event or change in circumstances occurs, then the Company will estimate the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the undiscounted future cash flows is less than the carrying amount of the related assets, then the Company will recognize an impairment loss. Assets to be disposed of are reclassified as assets held for sale at the lower of their carrying amount or fair value less costs to sell. Write-downs to fair value less disposal costs are reported as a part of loss from operations.
	The Company does not believe that there were any events or changes in circumstances which indicate that the carrying amounts of its long-lived assets may not be recoverable as of December 31, 2013 and 2012, respectively.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Restricted Deposits
	Long-term restricted deposits of $204,686 and $148,040 as of December 31, 2013 and 2012, respectively, consist primarily of cash deposits required as part of the sales tender process with governmental customers in Italy and cash deposits made in connection with capital and operating leases.
Foreign Currency Translations [Policy Text Block]	'
	Foreign Currency Translation
	The Company has operations that are located in Italy and is working to increase its presence in other international markets. Assets and liabilities as stated in the local reporting and functional currency are translated at the rate of exchange prevailing at the balance sheet date. Amounts in the consolidated statements of operations and comprehensive loss are translated at the average exchange rates for the period. The gains or losses that result from this process are shown in the “Accumulated Other Comprehensive Loss” in the consolidated statements of operations and comprehensive loss and consolidated statements of shareholders’ equity.
	The Company does not use financial derivatives to hedge exchange rate fluctuations.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Financial Instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and capital lease obligations approximate fair value due to the short-term maturity of the instruments. The Company does not speculate in the foreign exchange market.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Revenue and the related cost of sales on sales of test kits and instruments are recognized when risk of loss and title passes, which is generally at the time of shipment. Net revenue is comprised of gross revenue less provisions for expected product returns, allowances, discounts and warranty claims. Provisions and discounts for the years ended December 31, 2013 and 2012 were not significant.
	The Company recognizes milestone payments when earned, as evidenced by written acknowledgement from the collaborator, provided that the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, the milestone represents the culmination of an earnings process, the milestone payment is non-refundable and the Company’s past research and development services, as well as the Company’s ongoing commitment to provide research and development services under the collaboration, are charged at fees that are comparable to the fees that the Company customarily charges for similar research and development services.
	The Company also owns instruments that it places, under “reagent rental” programs common to the industry, for periods of time at customer facilities for usage with the Company’s products (“Equipment on Lease”). The instrument system, which remains the property of the Company, is utilized by customers to expedite the performance of certain tests and its use, including any required instrument service, is paid for by the customer through reagent kit purchases over the agreed upon contract period, typically three to five years. Upon completion of the contract period, the instrument is returned to the Company.
	Shipping and handling fees billed to customers are recognized in net revenue. Shipping and handling costs are included in cost of sales.
	The taxes that the Company has collected from its customers and remitted to governmental authorities are presented in the Company’s consolidated statements of operations and comprehensive loss on a net basis. Many of the Company’s customers are tax exempt organizations.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Costs
	Research and development costs related to future products are expensed as incurred. As described in Note 13, Related Party Transactions, the Company entered into a contract research and development agreement with ERBA Mannheim during 2011. Expenses incurred pursuant to that contract are included in cost of sales as the related revenues are recorded from the achievement of milestones.
Foreign Currency Transactions [Policy Text Block]	'
	Foreign Currency Transactions
	The Company has assets and liabilities held in foreign currency which are translated at period-end exchange rates, and revenues and expenses are translated at average rates prevailing during the period. Certain accounts receivable from customers are collected and certain accounts payable to vendors are payable in currencies other than the functional currencies of the Company. These amounts are adjusted to reflect period-end exchange rates. The Company recognized an unrealized gain on foreign currency transactions of $187,252 during the year ended December 31, 2013. The Company recognized an unrealized loss on foreign currency transactions of $55,793 during the year ended December 31, 2012.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation Plans
	Stock-based compensation expense for all share-based payment awards granted after January 1, 2006 is based on the grant-date fair value estimates. Compensation costs are recognized on a straight line basis over the requisite service period of the award, which is generally the option vesting term or immediately for options vested at the date of grant. Valuations are based on highly subjective assumptions about the future, including stock price volatility and exercise patterns. The fair value of share-based payment awards was estimated using the Black-Scholes option pricing model. Expected volatilities are based on the historical volatility of the Company’s stock. The Company uses historical data to estimate option exercise and employee terminations. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the United States Treasury yield curve in effect at the time of the grant. The Company estimates forfeitures for employee stock options and recognizes the compensation costs for only those options expected to vest. Forfeiture rates are determined for two groups, for directors and senior management and for all other employees, based upon historical experience. Estimated forfeitures are adjusted to actual forfeiture experience as needed. The cumulative effect of the change in forfeiture rates was immaterial for the years ended December 31, 2013 and 2012.
	As of December 31, 2013, the Company had stock-based employee compensation plans as described in Note 10, Shareholders’ Equity. The Company recorded total compensation expense of $134,000 for the year ended December 31, 2013 and $55,000 for the year ended December 31, 2012.
Earnings Per Share, Policy [Policy Text Block]	'
	Income (Loss) per Share
	Basic income (loss) per share excludes any dilution. It is based upon the weighted average number of shares of common stock outstanding during the period. Diluted loss per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock. As of December 31, 2013 and 2012, 450,000 and 15,854,204 shares of common stock, respectively, underlying stock options and warrants were not included in computing diluted income per share because their effects would be anti-dilutive.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurement
	The Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification Topic 820 (“ASC 820”) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability, in an orderly transaction between market participants at the measurement date.
	FASB ASC framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
	The three levels of the fair value hierarchy under FASB ASC 820 are described below:
		Level 1	Quoted market prices in active markets for identical assets or liabilities;
		Level 2	Inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted market prices in markets that are not active or other inputs that are either directly or indirectly observable; and
		Level 3	Unobservable inputs using estimates and assumptions developed by the Company, which reflect those that a market participant would use.
	The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of the observable inputs and minimize the use of unobservable inputs.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Standards
	In July 2012, the FASB issued ASU 2012-02 “Intangibles-Goodwill and Other.” This guidance relates to testing indefinite-lived assets for impairment and will give entities an option not to calculate annually the fair value of an indefinite-lived intangible asset if the entity determines that it is not more likely than not that the asset is impaired. This type of assessment based on qualitative factors is similar to the goodwill impairment testing in ASU 2011-08. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. These new requirements are not expected to have a material impact on the Company’s consolidated financial statements.
	In February 2013, the FASB issued ASU 2013-02 “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” This guidance requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income (loss) on the respective line items in net income (loss) if the amount being reclassified is required under US GAAP. For other amounts that are not required under US GAAP to be reclassified, in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under US GAAP that provide additional detail about those amounts. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. These new disclosure requirements are not expected to have a material impact on the Company’s consolidated financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Allowance For Doubtful Accounts [Table Text Block]	'
	The allowance for doubtful accounts was $1,064,739 and $995,662 as of December 31, 2013 and 2012, respectively, and activity for the years then ended was as follows:
		2013		2012
	Balance as of January 1	$	995,662	$	716,599
	Provision		39,559		625,935
	Write-offs		—		(361,229	)
	Effects of changes in foreign exchange rates		29,518		14,357
	Balance as of December 31	$	1,064,739	$	995,662
Schedule of Inventory, Current [Table Text Block]	'
	Inventories, net consist of the following as of December 31, 2013 and 2012:
		2013		2012
	Raw materials	$	3,123,380	$	1,712,199
	Work-in-process		624,454		664,880
	Finished goods		2,746,339		3,461,071
	Total inventories, net	$	6,494,173	$	5,838,150
Equipment On Lease Accumulated Amortization [Table Text Block]	'
	The cost of the Company’s owned instruments, which are placed under reagent rental programs at customer facilities for testing and usage of the Company’s products (see Note 2, Summary of Significant Accounting Policies, below under the heading Revenue Recognition), less accumulated amortization, consists of the following as of December 31, 2013 and 2012:
		2013		2012
	Equipment on lease, at cost	$	6,773,917	$	6,666,122
	Less accumulated amortization		6,187,132		6,080,801
		$	586,785	$	585,321
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets relate to the acquisition of Drew Scientific (as more fully described in Note 3, Acquisition of Drew Scientific, Inc.) and consist of the following as of December 31, 2013 and 2012:
		Estimated Useful Life (Years)		As of December 31, 2013							As of December 31, 2012
				Gross			Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
				Amount					Amount		Amount				Amount
	Customer relationships		4.8	$	1,026,532		$	266,957	$	759,575	$	1,026,532	$	53,096	$	973,436
	Trademarks/ tradenames		10		512,701			64,087		448,614		512,701		12,817		499,884
	Patents		7		309,057			53,168		255,889		309,057		9,972		299,085
	Lease rights		2		47,140			31,067		16,073		47,140		7,497		39,643
				$	1,895,430		$	415,279	$	1,480,151	$	1,895,430	$	83,382	$	1,812,048
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Amortization expense is computed principally on a straight-line basis and for the next five years approximates:
	Years Ending December 31,
	2014	$	324,000
	2015		306,000
	2016		306,000
	2017		216,000
	2018		94,000
		$	1,228,000

ACQUISITION_OF_DREW_SCIENTIFIC1

ACQUISITION OF DREW SCIENTIFIC, INC. (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'
	Below is a summary of assets acquired and liabilities assumed (rounded):
	Purchase price	$	6,500,000
	Fair value of assets acquired:
	Trade accounts receivable		1,211,000
	Inventories		2,093,000
	Prepaid and other current assets		140,000
	Property, plant and equipment		312,000
	Customer relationships		1,026,000
	Trademarks/tradenames		513,000
	Patents		309,000
	Other non-current assets		33,000
	Total fair value of assets acquired		5,637,000
	Fair value of liabilities assumed:
	Accounts payable		592,000
	Accrued expenses		844,000
	Deferred revenue		325,000
	Total fair value of liabilities assumed		1,761,000
	Fair value of net assets acquired		3,876,000
	Excess of purchase price over fair value of net assets acquired	$	2,624,000

GOODWILL_Tables

GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
	The components of the carrying amount of goodwill as of December 31, 2013 and 2012 are as follows:
		Gross Carrying Amount		Accumulated Impairment			Net Book
							Value
	ImmunoVision	$	6,722,725	$	(5,852,435	)	$	870,290
	JAS Diagnostics	$	2,624,329		—			2,624,329
		$	9,347,054	$	(5,852,435	)	$	3,494,619

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	'
	The provision (benefit) for income taxes consists of the following for the years ended December 31, 2013 and 2012:
		2013			2012
	Current:
	Domestic	$	—		$	10,500
	Foreign		50,266			30,856
	Deferred:
	Domestic		68,788			80,689
	Total	$	119,054		$	122,045
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	The components of income (loss) before income taxes are as follows for the years ended December 31, 2013 and 2012:
		2013			2012
	Domestic	$	1,056,504		$	(948,194	)
	Foreign		(261,622	)		(483,117	)
	Total	$	794,882		$	(1,431,311	)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The significant components of the net deferred income tax asset balances are as follows as of December 31, 2013 and 2012:
		2013			2012
	Current:
	Accounts receivable allowances	$	301,628		$	275,413
	Reserves and accruals		248,119			384,065
	Capitalized inventory costs		102,742			116,897
	Other		608			608
	Valuation allowance		(653,097	)		(776,983	)
	Deferred income taxes		—			—
	Long-term:
	Depreciation and basis differences on tangible and intangible assets		396,524			305,052
	Stock based compensation		410,987			359,397
	Other		(53,372	)		20,433
	Foreign net operating losses		1,005,901			931,213
	Domestic net operating losses		7,063.33			7,411,884
	Valuation allowance		(8,823,368	)		(9,027,979	)
	Net deferred tax asset	$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	A reconciliation of the difference between the expected provision (benefit) for income taxes using the statutory U.S. Federal tax rate and the Company’s actual provision (benefit) is as follows for the years ended December 31, 2013 and 2012:
		2013			2012
	Provision (benefit) for income taxes at U.S. Federal statutory	$	298,591		$	(500,959	)
	rate of 35%
						—
	Change in valuation allowance (excluding portion relating to stock options)		(328,498	)		239,458
	Foreign tax rate differential		63,480			293,028
	Global permanent differences		85,481			90,518
	Provision (benefit) for income taxes	$	119,054		$	122,045

ACCRUED_EXPENSES_AND_OTHER_LON1

ACCRUED EXPENSES AND OTHER LONG-TERM LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of the following as of December 31, 2013 and 2012:
		2013		2012
	Payroll costs	$	645,943	$	892,564
	Taxes, primarily VAT		800,756		572,095
	Professional fees		583,991		277,416
	Royalties		65,270		82,562
	Accrued acquisition costs		—		70,004
	Accrued plant closing costs		172,632		274,888
	Deferred revenue		249,159		406,840
	Other		376,679		233,078
	Balance as of December 31	$	2,894,430	$	2,809,447

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the stock option activity (both outstanding and exercisable) as of December 31, 2013 and 2012 and changes during the years ended December 31, 2013 and 2012 under the Performance Plan and the 2009 Plan:
		Number of Shares		Weighted Average Exercise Price
	Balance as of December 31, 2011		1,020,870	$	1.36
	Granted		100,000	$	0.55
	Balance as of December 31, 2012		1,120,870	$	1.28
	Granted		100,000	$	1.52
	Forfeited		50,000	$	0.65
	Balance as of December 31, 2013		1,170,870	$	1.33
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	Options Outstanding and Exercisable
	Range of Exercise Prices	Number of Shares		Weighted Average Remaining Contractual Life		Weighted
				(In Years)		Average Price
	$0.00 – $0.50		100,000		5.3	$	0.48
	$0.51 – $0.75		445,870		6.1	$	0.58
	$0.76 – $1.00		175,000		4.6	$	0.96
	$1.01 – $1.50		100,000		4.7	$	1.2
	$1.51 – $3.00		200,000		6.2	$	1.54
	$3.01 – $6.00		150,000		1.5	$	4.37
			1,170,870		5.3	$	1.33

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The table below sets forth net revenues, loss from operations, total assets and goodwill by region for the years ended December 31, 2013 and 2012:
		Domestic			European			Eliminations			Total
	December 31, 2013:
	External net sales	$	23,117,502		$	5,137,815		$	—		$	28,255,317
	Intercompany sales		488,764			19,615			(508,379	)		—
	Net revenue	$	23,606,266		$	5,157,430			($508,379	)	$	28,255,317
	Income (loss) from operations	$	1,137,515			($100,790	)	$	—		$	1,036,725
	Assets	$	40,287,271		$	6,047,420			($20,460,225	)	$	25,874,466
	Goodwill	$	3,494,619		$	—		$	—		$	3,494,619
	December 31, 2012:
	External net sales	$	14,316,923		$	5,032,081		$	—		$	19,349,004
	Intercompany sales		575,210			115,141			(690,351	)		—
	Net revenue	$	14,892,133		$	5,147,222			($690,351	)	$	19,349,004
	(Loss) from operations		($821,019	)		($382,142	)	$	—			($1,203,161	)
	Assets	$	38,785,080		$	6,163,472			($20,394,784	)	$	24,553,768
	Goodwill	$	3,494,619		$	—		$	—		$	3,494,619

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The future minimum lease payments for the next five years under these and other non-cancelable operating leases with initial or remaining terms of one year or more as of December 31, 2013 are as follows:
	2014	$	822,000
	2015		710,000
	2016		650,000
	2017		590,000
	2018		451,000
	Total minimum lease payments	$	3,223,000

ORGANIZATION_AND_OPERATIONS_De

ORGANIZATION AND OPERATIONS (Details Textual) (USD $)	Dec. 31, 2011	Sep. 01, 2010	Sep. 30, 2010	Oct. 03, 2012	Apr. 16, 2012	Dec. 29, 2011	Jun. 30, 2011	Apr. 08, 2011	Sep. 01, 2010
			ERBA Diagnostics Mannheim [Member]	ERBA Diagnostics Mannheim [Member]	ERBA Diagnostics Mannheim [Member]	ERBA Diagnostics Mannheim [Member]	ERBA Diagnostics Mannheim [Member]	ERBA Diagnostics Mannheim [Member]	ERBA Diagnostics Mannheim [Member]
			Stock Purchase Agreement [Member]	Stock Purchase Agreement [Member]	Stock Purchase Agreement [Member]	Stock Purchase Agreement [Member]	Stock Purchase Agreement [Member]	Stock Purchase Agreement [Member]	Stock Purchase Agreement [Member]
Organization And Basis Of Presentations [Line Items]	'	'	'	'	'	'	'	'	'
Equity Method Investment, Ownership Percentage	'	'	'	'	'	'	'	'	72.40%
Equity Method Investment, Aggregate Cost (in dollars)	'	'	'	'	'	'	'	$15,000,000	$15,000,000
Business Acquisition, Share Price	'	'	'	'	'	'	'	$0.75	$0.75
Stock Shares Issued Upon Exercise Of Class Of Warrant Or Right	20,000,000	'	'	4,666,666	600,000	8,666,667	6,666,667	'	600,000
Business Acquisition, Percentage of Voting Interests Acquired	'	72.40%	82.40%	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	15,333,334	'	'	'	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Financing Receivable, Allowance for Credit Losses [Line Items]	'	'
Balance as of January 1	$995,662	$716,599
Provision	39,221	195,940
Write-offs	0	-361,229
Effects of changes in foreign exchange rates	29,518	14,357
Balance as of December 31	$1,064,739	$995,662

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Raw materials	$3,123,380	$1,712,199
Work-in-process	624,454	664,880
Finished goods	2,746,339	3,461,071
Total inventories, net	$6,494,173	$5,838,150

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Equipment on lease, at cost	$6,773,917	$6,666,122
Less accumulated amortization	6,187,132	6,080,801
Equipment On Lease Net	$586,785	$585,321

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	$1,895,430	$1,895,430
Accumulated Amortization	415,279	83,382
Net Amount	1,480,151	1,812,048
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated Useful Life (Years)	'10 years	'
Gross Amount	512,701	512,701
Accumulated Amortization	64,087	12,817
Net Amount	448,614	499,884
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated Useful Life (Years)	'4 years 9 months 18 days	'
Gross Amount	1,026,532	1,026,532
Accumulated Amortization	266,957	53,096
Net Amount	759,575	973,436
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated Useful Life (Years)	'7 years	'
Gross Amount	309,057	309,057
Accumulated Amortization	53,168	9,972
Net Amount	255,889	299,085
Lease Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated Useful Life (Years)	'2 years	'
Gross Amount	47,140	47,140
Accumulated Amortization	31,067	7,497
Net Amount	$16,073	$39,643

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
2014	$324,000	'
2015	306,000	'
2016	306,000	'
2017	216,000	'
2018	94,000	'
Intangible assets, net	$1,480,151	$1,812,048

SUMMARY_OF_SIGNIFICANT_ACCOUNT8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Line Items]	'	'	'
Inventory, Net	$6,494,173	$5,838,150	'
Inventory Maturity Term	'5 years	'	'
Depreciation, Total	393,462	326,917	'
Amortization, Total	214,237	172,175	'
Amortization of Intangible Assets	331,897	83,382	'
Restricted Cash and Cash Equivalents, Noncurrent	204,686	148,040	'
Foreign Currency Transaction Gain (Loss), Unrealized	187,252	-55,793	'
Allowance for Doubtful Accounts Receivable, Current	1,064,739	995,662	716,599
Inventory Valuation Reserves	1,129,000	816,000	'
Forecasted Cash Flow Period	'5 years	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	450,000	15,854,204	'
Business Acquisition, Date of Acquisition Agreement	3-Oct-12	'	'
Fair Value Inputs, Long-term Revenue Growth Rate	3.00%	'	'
Fair Value Inputs, Discount Rate	19.00%	20.00%	'
Share-based Compensation, Total	134,000	55,000	'
Accounting Standards Update 201202 [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
New Accounting Pronouncement or Change in Accounting Principle, Description	'In July 2012, the FASB issued ASU 2012-02 Intangibles-Goodwill and Other. This guidance relates to testing indefinite-lived assets for impairment and will give entities an option not to calculate annually the fair value of an indefinite-lived intangible asset if the entity determines that it is not more likely than not that the asset is impaired. This type of assessment based on qualitative factors is similar to the goodwill impairment testing in ASU 2011-08. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. These new requirements are not expected to have a material impact on the Companys consolidated financial statements.	'	'
Accounting Standards Update 201302 [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
New Accounting Pronouncement or Change in Accounting Principle, Description	'In February 2013, the FASB issued ASU 2013-02 Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. This guidance requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income (loss) on the respective line items in net income (loss) if the amount being reclassified is required under US GAAP. For other amounts that are not required under US GAAP to be reclassified, in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under US GAAP that provide additional detail about those amounts. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. These new disclosure requirements are not expected to have a material impact on the Companys consolidated financial statements.	'	'
Minimum [Member] | Building and Building Improvements [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'
Minimum [Member] | Machinery and Equipment [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'
Minimum [Member] | Furniture and Fixtures [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'
Maximum [Member] | Building and Building Improvements [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'20 years	'	'
Maximum [Member] | Machinery and Equipment [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'10 years	'	'
Maximum [Member] | Furniture and Fixtures [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'10 years	'	'
Hepatitis Product [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Inventory, Net	'	$100,000	'

ACQUISITION_OF_DREW_SCIENTIFIC2

ACQUISITION OF DREW SCIENTIFIC, INC. (Details) (USD $)	Dec. 31, 2013
Acquisitions [Line Items]	'
Purchase price	$6,500,000
Fair value of assets acquired:	'
Trade accounts receivable	1,211,000
Inventories	2,093,000
Prepaid and other current assets	140,000
Property, plant and equipment	312,000
Other non-current assets	33,000
Total fair value of assets acquired	5,637,000
Fair value of liabilities assumed:	'
Accounts payable	592,000
Accrued expenses	844,000
Deferred revenue	325,000
Total fair value of liabilities assumed	1,761,000
Fair value of net assets acquired	3,876,000
Excess of purchase price over fair value of net assets acquired	2,624,000
Patents [Member]	'
Fair value of assets acquired:	'
Finite-lived Intangible Assets, Fair Value Disclosure	309,000
Customer Relationships [Member]	'
Fair value of assets acquired:	'
Finite-lived Intangible Assets, Fair Value Disclosure	1,026,000
Trademarks [Member]	'
Fair value of assets acquired:	'
Finite-lived Intangible Assets, Fair Value Disclosure	$513,000

ACQUISITION_OF_DREW_SCIENTIFIC3

ACQUISITION OF DREW SCIENTIFIC, INC. (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2012	Oct. 31, 2012	Oct. 03, 2012
		Trademarks [Member]	Patents [Member]	Customer Relationships [Member]	Drew Scientific Inc [Member]	Drew Scientific Inc [Member]	Drew Scientific Inc [Member]	Drew Scientific Inc [Member]	Drew Scientific Inc [Member]	Drew Scientific Inc [Member]
									Second Closing [Member]	Second Closing [Member]
Acquisitions [Line Items]	'	'	'	'	'	'	'	'	'	'
Business Combination Cost Of Acquired Entity Purchase Price	$6,500,000	'	'	'	'	'	'	'	'	$6,500,000
Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares	'	'	'	'	'	'	'	'	8,666,667	'
Business Acquisition, Share Price	'	'	'	'	'	'	'	'	'	$0.75
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'	'10 years	'7 years	'4 years 9 months 18 days	'	'	'	'	'	'
Business Acquisition, Cost Of Acquired Entity, Transaction Costs	'	'	'	'	'	'	'	211,000	'	'
Business Acquisition Date	'	'	'	'	'	'	'	'	3-Oct-12	'
Lease Buy Out Cost	'	'	'	'	'	'	'	'	160,000	'
Severance Costs	'	'	'	'	'	'	'	'	118,000	'
Business Acquisition, Pro Forma Revenue	'	'	'	'	3,391,000	13,755,000	29,264,000	'	'	'
Business Acquisition, Pro Forma Net Income (Loss)	'	'	'	'	$238,000	$1,614,000	$1,368,000	'	'	'
Business Acquisition Pro Forma Net Loss Per Share	'	'	'	'	'	'	0.04%	'	'	'

GOODWILL_Details

GOODWILL (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'
Gross Carrying Amount	$9,347,054	'
Accumulated Impairment	-5,852,435	'
Net Book Value	3,494,619	3,494,619
Immuno Vision [Member]	'	'
Goodwill [Line Items]	'	'
Gross Carrying Amount	6,722,725	'
Accumulated Impairment	-5,852,435	'
Net Book Value	870,290	'
Jas Diagnostics [Member]	'	'
Goodwill [Line Items]	'	'
Gross Carrying Amount	2,624,329	'
Accumulated Impairment	0	'
Net Book Value	$2,624,329	'

PRODUCT_LICENSE_Details_Textua

PRODUCT LICENSE (Details Textual)	3 Months Ended	12 Months Ended						12 Months Ended
	Dec. 31, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2008	Sep. 30, 2004	Dec. 31, 2013	Dec. 31, 2012
	USD ($)	USD ($)	USD ($)	EUR (€)	EUR (€)	USD ($)	EUR (€)	Product License [Member]	Product License [Member]
								USD ($)
Indefinite-lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'
Finite-Lived License Agreements, Gross	'	'	'	'	'	'	€ 1,000,000	'	'
Payment For Finite Lived License Agreements	'	'	'	'	900,000	'	'	'	'
License Fees Payable	'	132,000	'	100,000	'	'	'	'	'
Impairment of Intangible Assets, Finite-lived	400,000	'	'	'	'	'	'	'	'
Cash Flow Annual Discount Rate	'	'	'	'	'	'	'	'	23.00%
Finite Lived Intangible Assets After Impairment Charges	282,936	'	'	'	'	'	'	'	'
Other Intangible Assets, Net	'	226,349	282,936	'	'	682,936	'	'	'
Amortization of Intangible Assets	'	331,897	83,382	'	'	'	'	57,000	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	'	324,000	'	'	'	'	'	57,000	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	'	306,000	'	'	'	'	'	57,000	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	'	306,000	'	'	'	'	'	57,000	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	'	$216,000	'	'	'	'	'	$57,000	'

CONCENTRATION_OF_CREDIT_RISK_D

CONCENTRATION OF CREDIT RISK (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]	'	'
Accounts receivable, net	$5,546,715	$5,643,359
Concentration Risk, Percentage	18.00%	26.00%
Revenues	5,138,000	5,032,000
Reinsurance Retention Policy, Excess Retention, Amount Reinsured	954,020	'
Ceded Credit Risk, Concentrated Credit Risk [Member]	'	'
Concentration Risk [Line Items]	'	'
Reinsurance Recoverables	1,704,000	'
Credit Concentration Risk [Member] | Hospitals and Laboratories Controlled By Italian Government [Member]	'	'
Concentration Risk [Line Items]	'	'
Entity Wide Accounts Receivable Major Customer Percentage	24.00%	27.00%
Amount Due From Hospitals and Laboratories In Total Net Accounts	1,700,000	1,719,000
Italy [Member]	'	'
Concentration Risk [Line Items]	'	'
Accounts receivable, net	$4,647,000	$4,394,000

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current:	'	'
Domestic	$0	$10,500
Foreign	50,266	30,856
Deferred:	'	'
Domestic	68,788	80,689
Total	$119,054	$122,045

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income taxes [Line Items]	'	'
Domestic	$1,056,504	($948,194)
Foreign	-261,622	-483,117
Total	$794,882	($1,431,311)

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current:	'	'
Accounts receivable allowances	$301,628	$275,413
Reserves and accruals	248,119	384,065
Capitalized inventory costs	102,742	116,897
Other	608	608
Valuation allowance	-653,097	-776,983
Deferred income taxes	0	0
Long-term:	'	'
Depreciation and basis differences on tangible and intangible assets	396,524	305,052
Stock based compensation	410,987	359,397
Other	-53,372	20,433
Foreign net operating losses	1,005,901	931,213
Domestic net operating losses	7,063,328	7,411,884
Valuation allowance	-8,823,368	-9,027,979
Net deferred tax asset	$0	$0

INCOME_TAXES_Details_3

INCOME TAXES (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income taxes [Line Items]	'	'
Provision (benefit) for income taxes at U.S. Federal statutory rate of 35%	$298,591	($500,959)
Change in valuation allowance (excluding portion relating to stock options)	-328,498	239,458
Foreign tax rate differential	63,480	293,028
Global permanent differences	85,481	90,518
Provision (benefit) for income taxes	$119,054	$122,045

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Sep. 01, 2010
Income taxes [Line Items]	'	'	'
Deferred Tax Liabilities, Goodwill	$578,153	$509,365	'
Deferred Tax Liabilities, Net	578,153	509,365	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%	'
PROVISION FOR INCOME TAXES	119,054	122,045	'
Domestic net operating losses	7,063,328	7,411,884	'
Operating Loss Carryforwards, Expiration Date	1-Dec-22	'	'
Business Acquisition, Percentage of Voting Interests Acquired	'	'	72.40%
Operating Loss Carryforwards, Limitations on Use	'currently limited to approximately $825,000 per year, plus both any limitation unused since the acquisition	'	'
Income Tax Examination, Likelihood of Unfavorable Settlement	'greater than 50% likelihood	'	'
Excise and Sales Taxes	185,000	'	'
Domestic Tax Authority [Member]	'	'	'
Income taxes [Line Items]	'	'	'
Domestic net operating losses	$18,110,000	'	'

EMPLOYEE_BENEFIT_PLANS_Details

EMPLOYEE BENEFIT PLANS (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'
Defined Contribution Plan Matching Contribution Amount	$112,970

ACCRUED_EXPENSES_AND_OTHER_LON2

ACCRUED EXPENSES AND OTHER LONG-TERM LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Payables And Accruals [Line Items]	'	'
Payroll costs	$645,943	$892,564
Taxes, primarily VAT	800,756	572,095
Professional fees	583,991	277,416
Royalties	65,270	82,562
Accrued Acquisition Costs	0	70,004
Accrued plant closing costs	172,632	274,888
Deferred revenue	249,159	406,840
Other	376,679	233,078
Balance as of December 31	$2,894,430	$2,809,447

ACCRUED_EXPENSES_AND_OTHER_LON3

ACCRUED EXPENSES AND OTHER LONG-TERM LIABILITIES (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Payables And Accruals [Line Items]	'	'
Other Liabilities, Noncurrent	$1,027,425	$993,980

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details) (Plan 2009 [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Plan 2009 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Balance, Number of Shares	1,120,870	1,020,870
Granted, Number of Shares	100,000	100,000
Forfeited, Number of Shares	50,000	'
Balance, Number Of Shares	1,170,870	1,120,870
Balance, Weighted Average Excercise Price	$1.28	$1.36
Granted, Weighted Average Excercise Price	$1.52	$0.55
Forfeited, Weighted Average Excercise Price	$0.65	'
Balance, Weighted Average Excercise Price	$1.33	$1.28

SHAREHOLDERS_EQUITY_Details_1

SHAREHOLDERS' EQUITY (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding and Exercisable Number Of Shares	1,170,870
Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years)	'5 years 3 months 18 days
Options Outstanding and Exercisable Weighted Average Exercise Price	$1.33
Stock Option One [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices, Minimum	$0
Range of Exercise Prices, Maximum	$0.50
Options Outstanding and Exercisable Number Of Shares	100,000
Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years)	'5 years 3 months 18 days
Options Outstanding and Exercisable Weighted Average Exercise Price	$0.48
Stock Option Two [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices, Minimum	$0.51
Range of Exercise Prices, Maximum	$0.75
Options Outstanding and Exercisable Number Of Shares	445,870
Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years)	'6 years 1 month 6 days
Options Outstanding and Exercisable Weighted Average Exercise Price	$0.58
Stock Option Three [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices, Minimum	$0.76
Range of Exercise Prices, Maximum	$1
Options Outstanding and Exercisable Number Of Shares	175,000
Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years)	'4 years 7 months 6 days
Options Outstanding and Exercisable Weighted Average Exercise Price	$0.96
Stock Option Four [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices, Minimum	$1.01
Range of Exercise Prices, Maximum	$1.50
Options Outstanding and Exercisable Number Of Shares	100,000
Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years)	'4 years 8 months 12 days
Options Outstanding and Exercisable Weighted Average Exercise Price	$1.20
Stock Option Five [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices, Minimum	$1.51
Range of Exercise Prices, Maximum	$3
Options Outstanding and Exercisable Number Of Shares	200,000
Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years)	'6 years 2 months 12 days
Options Outstanding and Exercisable Weighted Average Exercise Price	$1.54
Stock Option Six [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices, Minimum	$3.01
Range of Exercise Prices, Maximum	$6
Options Outstanding and Exercisable Number Of Shares	150,000
Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years)	'1 year 6 months
Options Outstanding and Exercisable Weighted Average Exercise Price	$4.37

SHAREHOLDERS_EQUITY_Details_Te

SHAREHOLDERS' EQUITY (Details Textual) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2002	Mar. 31, 2001	Jun. 30, 2009	Jun. 03, 2009	Jun. 10, 2011	Mar. 14, 2001	Jun. 10, 2011	Mar. 14, 2001
				Ivax Diagnostics [Member]	Plan 2009 [Member]	Plan 2009 [Member]	Minimum [Member]	Minimum [Member]	Maximum [Member]	Maximum [Member]
								Ivax Diagnostics [Member]		Ivax Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Conversion of Stock, Shares Converted	'	'	'	20,000,000	'	'	'	'	'	'
Common Stock, Shares Authorized	100,000,000	100,000,000	'	'	'	'	50,000,000	25,000,000	100,000,000	50,000,000
Total Number Of Shares Of Common Stock Repurchased	'	'	1,184,573	'	'	'	'	'	'	'
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	'	'	2,000,000	'	'	'	'	'	'	'
Shares Of Common Stock Remaining Available For Grant	'	'	'	'	'	1,561,072	'	'	'	'
Shares Of Common Stock Authorized For Grant	'	'	'	'	'	2,000,000	'	'	'	'
Shares Of Common Stock Performance Plan Authorized For Grant	'	'	'	'	'	2,000,000	'	'	'	'
Options Term	'	'	'	'	'10 years	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$1,884,000	$179,000	'	'	'	'	'	'	'	'
Shares Authorized Performance Plan Description	'The Performance Plan authorized the grant of up to 2,000,000 shares of common stock of the Company to key employees, officers, directors and consultants.	'	'	'	'	'	'	'	'	'

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'
External net sales	$28,255,317	$19,349,004
Intercompany sales	0	0
Net revenue	28,255,317	19,349,004
Income (loss) from operations	1,036,725	-1,203,161
Assets	25,874,466	24,553,768
Goodwill	3,494,619	3,494,619
Domestic [Member]	'	'
Segment Reporting Information [Line Items]	'	'
External net sales	23,117,502	14,316,923
Intercompany sales	488,764	575,210
Net revenue	23,606,266	14,892,133
Income (loss) from operations	1,137,515	-821,019
Assets	40,287,271	38,785,080
Goodwill	3,494,619	3,494,619
European [Member]	'	'
Segment Reporting Information [Line Items]	'	'
External net sales	5,137,815	5,032,081
Intercompany sales	19,615	115,141
Net revenue	5,157,430	5,147,222
Income (loss) from operations	-100,790	-382,142
Assets	6,047,420	6,163,472
Goodwill	0	0
Eliminations [Member]	'	'
Segment Reporting Information [Line Items]	'	'
External net sales	0	0
Intercompany sales	-508,379	-690,351
Net revenue	-508,379	-690,351
Income (loss) from operations	0	0
Assets	-20,460,225	-20,394,784
Goodwill	$0	$0

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
Commitments And Contingencies Disclosure [Line Items]	'
2014	$822,000
2015	710,000
2016	650,000
2017	590,000
2018	451,000
Total minimum lease payments	$3,223,000

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	USD ($)	USD ($)	Immunovision Inc [Member]	Immunovision Inc [Member]	Delta Biologicals [Member]	Delta Biologicals [Member]	Jas Diagnostics [Member]
				July 31, 2014 [Member]	July 31, 2016 [Member]	USD ($)	EUR (€)	USD ($)
				USD ($)	USD ($)
Commitments And Contingencies Disclosure [Line Items]	'	'	'	'	'	'	'	'
Operating Leases, Rent Expense	$7,000	'	'	$72,000	$73,440	$159,000	€ 120,000	'
Capital Leases Agreement Term	'	'	'36 months	'	'	'	'	'
2014	822,000	'	'	'	'	'	'	391,150
2015	710,000	'	'	'	'	'	'	401,280
2016	650,000	'	'	'	'	'	'	417,657
2017	590,000	'	'	'	'	'	'	434,024
2018	451,000	'	'	'	'	'	'	451,386
Operating Leases, Rent Expense, Net, Total	735,000	496,000	'	'	'	'	'	'
Equipment Lease Original Price Percentage	'	'	22.00%	'	'	'	'	'
Capital Leased Assets, Gross	'	'	222,000	'	'	'	'	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	'	'	91,000	'	'	'	'	'
Cost of Goods Sold, Depreciation	28,000	25,000	'	'	'	'	'	'
Capital Lease Obligations, Current	0	21,947	'	'	'	'	'	'
Interest Expense	$15,000	$15,000	'	'	'	'	'	'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2012

Oct. 31, 2012

Oct. 03, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Apr. 16, 2012

Oct. 03, 2012

Dec. 29, 2011

Jun. 30, 2011

Apr. 08, 2011

Sep. 01, 2010

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

USD ($)

USD ($)

Drew Scientific Inc [Member]

Drew Scientific Inc [Member]

Drew Scientific Inc [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim [Member]

Director [Member]

Transasia Bio-Medicals Ltd [Member]

Transasia Bio-Medicals Ltd [Member]

Erba Diagnostics Mannheim and Transasia [Member]

Erba Diagnostics Mannheim and Transasia [Member]

Erba Diagnostics France [Member]

Erba Diagnostics France [Member]

Erba Diagnostics France [Member]

Erba Diagnostics France [Member]

Subsidiaries [Member]

Subsidiaries [Member]

Immunovision Inc [Member]

Immunovision Inc [Member]

USD ($)

Second Closing [Member]

Second Closing [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Stock Purchase Agreement [Member]

Stock Purchase Agreement [Member]

Stock Purchase Agreement [Member]

Stock Purchase Agreement [Member]

Stock Purchase Agreement [Member]

Stock Purchase Agreement [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

EUR (€)

Director [Member]

Director [Member]

Director [Member]

Director [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from Related Parties

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$606,000

$501,000

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Amounts of Transaction

'

'

'

'

'

'

'

'

'

'

'

754,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

24,000

Related Party Transaction Due To Related Party

'

'

'

'

'

'

'

'

799,000

621,700

186,000

133,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and Development Arrangement, Contract to Perform for Others, Compensation Earned

'

'

'

'

'

'

896,000

675,000

836,000

650,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

462,500

350,000

'

'

'

'

Accounts Receivable, Related Parties, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,835,000

644,000

'

'

'

'

'

'

'

'

Business Acqusition Acquired Entity Purchase Price

'

'

'

'

'

6,500,000

'

'

'

'

'

'

'

3,500,000

6,500,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

'

'

'

'

8,666,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Share Price

'

'

'

'

'

$0.75

'

'

'

'

'

'

'

'

'

'

$0.75

$0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity Method Investment, Aggregate Cost (in dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition Warrant Or Right Issued Number Of Warrantor Right Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Shares Issued Upon Exercise Of Class Of Warrant Or Right

'

'

20,000,000

'

'

'

'

'

'

'

'

'

600,000

4,666,666

8,666,667

6,666,667

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Cost of Acquired Entity, Transaction Costs

'

'

'

211,000

'

'

'

'

'

'

'

'

'

'

'

399,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Of Common Stock, Net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,600,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

0.75

0.75

0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Or Right Exercisable Number

14,733,334

14,733,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

'

'

'

'

'

'

'

'

'

450,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

19,400,000

19,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Fee Annual Minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

Consulting Agreement Consideration Per Month

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

Research and Development Expense

1,920,171

1,122,537

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

64,900

50,000

'

'

'

'

Reimbursement Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

913,000

'

'

'

'

'

'

Accrued Royalty Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000

$10,000

'

'

REVOLVING_LINE_OF_CREDIT_Detai

REVOLVING LINE OF CREDIT (Details Textual) (USD $)	12 Months Ended		1 Months Ended	12 Months Ended			1 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	Jun. 10, 2011	Mar. 31, 2013	Dec. 31, 2013	Mar. 01, 2013	Mar. 01, 2013	Mar. 01, 2013
			Diamedix Corporation [Member]	Diamedix Corporation [Member]	Diamedix Corporation [Member]	Diamedix Corporation [Member]	Citibank NA [Member]	Citibank NA [Member]	Citibank NA [Member]	Citibank NA [Member]	Citibank NA [Member]
										Maximum [Member]	Minimum [Member]
Short-term Debt [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	'	'	'	$975,000	'	'	$2,000,000	'	'
Line of Credit Facility,Interest Rate Description	'	'	'30-day LIBOR plus 4.00%	'	'	'	'30-day LIBOR plus 1.75%	'	'	'	'
Minimum Net Worth Required for Compliance	'	'	'	'	'	'	'	'	8,500,000	'	'
Debt Issuance Cost	'	'	'	975,000	101,482	'	'	'	'	'	'
Line of Credit Facility, Amount Outstanding	'	1,905,000	'	'	'	'	'	'	'	'	'
Leverage Ratio	'	'	'	'	'	'	'	'	'	2	1
Line of Credit Facility, Expiration Date	'	'	'	'	10-Jun-13	'	'	31-Dec-14	'	'	'
Amortization Period Of Debt Issuance Costs	'24 months	'	'	'	'	'	'	'	'	'	'
Amortization of Leased Asset	$50,736	'	'	'	'	'	'	'	'	'	'
Line of Credit Facility, Interest Rate at Period End	'	1.92%	'	'	'	'	'	'	'	'	'